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ABBREVIATIONS 
°C                    grad Celsius 
μ                      micro (10-6) 
5L/5L               homozygous for 5-leucin-repeats at micro-satellite marker D18S880 of                        
CN1 
Ab                    Antibody 
ACE                 Angiotensin Converting Enzyme 
ACEi                Angiotensin converting enzyme inhibitor 
ACR                 albumin creatinine ratio 
ADA                 American Diabetes Association 
AER                 Albumin excretion rate 
AGEs               advanced glycation end products 
ALEs                advanced lipoxidation end products 
APS                 ammoniumpersulfate 
ARB                 angiotensin converting enzyme blocker 
ATLAS             anti-CNDP1 antibody produced in rabbit from Sigma-Aldrich 
ATP                 adenosine triphosphate 
BMI                  body mass index 
bp                    base pair 
BSA                 bovine serum albumin 
BTBR               Black and Tan, BRachyuric 
BUN                 blood urea nitrogen 
cAMP               cyclic adenosine monophosphate 
CARNS            carnosine synthase 
cDNA               complementary DNA 
CKD                 chronic kidney disease 
Cl                     chloride 
CN1                 carnosinase 
CNDP1            carnosinase dipeptidase 1 gene 
COX-1             cyclo-oxygenase 1 
Cr                    creatinine 
CTG                 cytosine-thymine-guanine 
dATP               deoxy-adenosine triphosphate 
db                    diabetes   
Abbreviations 
2 
 
DBP                 diastolic blood pressure 
dCTP               deoxy-cytidinetriphosphate 
ddH2O              double-destilled water 
dGTP               deoxy-guanosinetriphosphate 
DKD                 diabetic kidney disease 
DM                   diabetes mellitus 
DMSO              dimethylsulfoxide 
DN                   diabetic nephropathy 
DNA                 deoxyribonucleic acid 
dNTP               dideoxy-nucleoside triphosphate 
DTT                 dithiothreitol 
E. coli              Escherichia coli 
EDTA               ethylene diaminetetraacetic acid 
eGFR               estimated glomerular filtration rate 
ELISA              enzyme-linked immunosorbent assay 
ESRD              end stage renal disease 
F                      forward or phenylalanine 
Fig.                  figure 
FPG                 fasting plasma glucose 
g                      gram 
G                     glycine or guanine 
Glo-1               Glyoxalase-1 
Glo-2               Glyoxalase-2 
GBM                glomerular basement membrane 
GFP                 green fluorescent protein 
GFR                 glomerular filtration rate 
GLP-1              Glucagon-like peptide-1 
GPX                glutathione peroxidase 
GRX                glutaredoxin 
GSH                glutathione 
GSSG              glutathione disulfide   
H2O2                        hydrogen peroxide 
HbA1c             glycated hemoglobin 
HCD                histidine-containing peptide 
HCl                  hydrogen chloride 
Abbreviations 
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hCN1               human CN1 
HNE                 4-Hydroxy-2-nonenal 
hr(s)                 hour(s) 
HUVECs          human umbilical vein endothelial cells 
HRP                 horseradish peroxidase 
IDNT                Irbesartan Diabetic Nephropathy Trial 
IgG                   immunoglobulin G 
IU                     international units 
JNK                  c-Jun N-terminal kinases 
K                                 potassium 
kb                     kilo base pair 
KCl                   potassium chloride 
kDa                  kilo-dalton 
KDIGO             Kidney Disease Improving Global Outcomes 
kg                     kilogram 
l                        liter 
L                       leucin 
Log                   logarithm 
m                      milli 
M                     molar (mol/l) 
MAPK              mitogen-activated protein kinase 
MGO                Methylglyoxal 
Mg                   Magnesium 
MgCl2              magnesium chloride 
min                   minute 
mRNA              messenger RNA 
n                       nano (10-9) 
Na                    sodium 
NF                    nuclease free 
NF-κB               nuclear factor kappa-light-chain-enhancer of activated B cells 
ns                     not significant 
nm                   nanometer 
nt                     nucleotide 
OD                   optical density 
ob                    obesity 
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OGTT              oral glucose tolerance test 
PBS                 phosphate buffered saline 
PCR                 polymerase chain reaction 
POD                 peroxidase 
PVDF               polyvinylidene fluoride 
R                      reverse 
RAS                 renin angiotensin system 
Redox              reduction–oxidation reaction 
RENAAL          Reduction in End-Points in Non-Insulin Dependent Diabetes Mellitus
     With the Angiotensin II Antagonist Losartan 
RNA                 ribonucleic acid 
RNAse             ribonuclease 
RCS                 reactive carbonyl species  
ROS                 reactive oxygen species 
rpm                  revolutions per minute 
RT                    room temperature 
RT-PCR           reverse transcription polymerase chain reaction 
s                      second 
sAlb                 serum albumin 
SBP                 systolic blood pressure 
Scr                   serum creatinine 
SD                   standard deviation 
SDS                 sodium dodecyl sulfate 
SDS-PAGE      SDS-Polyacrylamide-Gel-electrophoresis 
seq                   sequence 
SGLT               Sodium-glucose linked transporter 
SOD                 superoxide dismutase 
STZ                  streptozotocin 
T1DM               type 1 diabetes 
T2DM               type 2 diabetes 
TAE                 Tris-Acetat-EDTA 
Taq                   thermostable DNA-polymerase 
TBS                 Tris buffered saline 
TBS-T              Tris buffered saline with 0,01% Tween20 
TEMED            Tetramethylethylenediamine 
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TG                   Triglyceride 
Tris                  Tris(hydroxymethyl)-aminoethane 
Tm                   melting temperature 
TTR                 transthyretin 
UACR              urine albumin creatinine ratio 
uAlb                 urine albumin 
uCr                   urine creatinine 
UMM                Clinical Faculty Mannheim (Universitätsklinikum Mannheim) 
UV                   ultraviolet 
USA                 United States of America 
UF                    ultrafiltration 
W                     watt 
wt                     wild type 
Zn                     zinc
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1 INTRODUCTION 
  Diabetes mellitus: Definition and epidemiology  1.1
Diabetes Mellitus is a metabolic disorder characterized by chronic hyperglycemia 
affecting more than 425 million worldwide1. It imparts high morbidity and mortality 
and thus it is considered a major health problem urging to take action to reduce 
health care costs2.There are two main types of diabetes Mellitus, i.e. type 1 and type 
2, of which the latter contributes foremost to the overall  prevalence2. Type 1 diabetes 
mellitus (T1DM) is an auto-immune disease in which destruction of  beta cells leads 
to absolute insulin deficiency and consequently to hyperglycemia. In contrast, T2DM 
is initially driven by insulin resistance followed by a progressive decrease in insulin 
secretory capacity with time. Apart from age and lifestyle-related factors also genetic 
factors contribute to the development of T2DM. As such T2DM aggregates in families 
with currently more than 60 genetic traits reported to be associated with risks to 
develop diabetes3.   
 
Diabetes is not only associated with microvascular complications (nephropathy, 
neuropathy and retinopathy) but also accelerates atherosclerosis independently of 
other traditional cardiovascular risk factors4,5. Although the risk for developing 
microvascular complications is proportional to both the severity and duration of 
hyperglycemia6, T2DM is usually not detected until late in the course of 
cardiovascular disease (CVD) and therefore, many patients are already suffering 
from complications at or shortly after diagnosis of T2DM. Because of the strong 
association between diabetes and cardiovascular disease (CVD)7, cardiovascular 
mortality in diabetic patients is high, accounting for 52% of deaths in T2DM and 44% 
in type 1 diabetes mellitus (T1DM)8.  
  
According to the American Diabetes Association (ADA), diabetes is diagnosed based 
on plasma glucose parameters, i.e. fasting plasma glucose (FPG), oral glucose 
tolerance test (OGTT)9, or the recently added HbA1c criteria10. HbA1c is an indicator 
of chronic glycaemia reflecting average glucose levels over a period of 2-3 months 
and it is used as a standard biomarker of proper glycemic management11. 
Although the currently used therapeutics targets, e.g. blood pressure-12 , lipid13–15 
and glycemic control16–18, have proven to be highly efficacious to decrease the 
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incidence and to retard the progression of microvascular complications, the 
association of tight glycemic control and reduction of macrovascular complications is 
more ambiguous19. Recent clinical interventions trials with new therapeutics such as 
sodium glucose cotransport (SGLT-2) inhibitors and glucagon-like peptide (GLP-1) 
agonists have consistently demonstrated cardiovascular benefits and weight loss 
effects in patients with T2DM20–23. Yet, early screening and early lifestyle intervention 
programs are likely to be the most efficacious and cost reducing strategies to 
counteract the increasing incidence of T2DM and its associated complications 24. 
 
 Diabetic nephropathy 1.2
1.2.1 Epidemiology 
 
Diabetic nephropathy (DN) is considered to be one of the most devastating 
microvascular complications of diabetes mellitus, developing in nearly one third of 
patients with type 1 or type 2 diabetes25. It is by far the most common cause of 
chronic kidney disease (CKD) worldwide, frequently leading to end-stage renal 
disease (ESRD) and the need for renal replacement therapy26. The prevalence of DN 
largely differs amongst ethnic groups, with Native Americans, African Americans and 
indigenous Australians having the highest prevalence of ESRD due to diabetes27. 
DN also imparts an increased risk for cardiovascular disease and death in patients 
with type 1 and type 2 diabetes28. Accordingly, the annual cardiovascular death rate 
is 2% and 3.5% in patients with microalbuminuria and macroalbuminuria respectively, 
increasing up to 12.1% in patients on renal replacement therapy29. 
 
1.2.2 Pathophysiology and current therapies 
 
DN typically develops through sequential phases, commonly starting with a 
supraphysiologic increase in the glomerular filtration rate (GFR) known as 
hyperfiltration. This phenomenon is an adaptive response to functional nephron mass 
reduction and to hemodynamic  and  metabolic changes prevailing in diabetes and 
obesity30.  
This increase in GFR is followed by intermittent episodes of microalbuminuria which 
progress to persistent microalbuminuria in one third of the patients and reflects an 
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initial loss of permselectivity of the glomerular basement membrane. Thus, 
abnormalities in albuminuria excretion are often the first clinical manifestation of DN. 
The classification of albuminuria according to the Kidney Disease Improving Global 
Outcomes (KDIGO) guidelines 2012 are displayed in  Table 1.31. 
 
Table 1.   Albuminuria categories according to KDIGO 2012 
  ACRa(approximate equivalent)  
Category AERb (mg/24h)     (mg/mmol)                (mg/g) Terms 
A1 <30 <3 <30 Normal to mildly increased 
A2 30-300 3-30 30-300 Moderately increased 
A3 >300 >30 >300 Severely increased 
   
a
Albumin-to-creatinine ratio, 
b 
Albumin excretion rate 
 
The stage of microalbuminuria is followed by macroalbuminuria and progressive 
decline in GFR32,33. These clinical signs are often associated with structural 
pathological changes such as podocyte injury, mesangial expansion and 
glomeruloesclerosis34.  
The increase in albuminuria is often accompanied by comorbidities such as diabetic 
retinopathy and hypertension. In the last stage of the disease, decline in GFR 
progresses to ESRD which ultimately results in the need of renal replacement 
therapy. Importantly, both low GFR and albuminuria are independent predictors of 
mortality and progression to ESRD35. 
Current treatment modalities for diabetic nephropathy focus on four main targets: 
cardiovascular risk reduction, glycemic control, blood pressure control and inhibition 
of the renin-angiotensin system (RAS)36. Observational data from large clinical 
intervention trials in patients with T2DM and proteinuria, i.e. IDNT (Irbesartan 
Diabetic Nephropathy Trial) and the RENAAL (Reduction in End-Points in Non-Insulin 
Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan) have 
demonstrated that RAS blockade with angiotensin converting enzyme (ACE) 
inhibitors or angiotensin receptor blockers (ARBs) retards disease onset and 
progression of albuminuria, independently of blood pressure control37–39. Additionally, 
emerging therapies such as the SGLT2 inhibitors have been recently approved for 
the treatment of diabetes and have shown positive effects on renal outcomes36. 
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 Methylglyoxal: Role of carbonyl and oxidative stress  1.3
 
Although the value of appropriate glycemic control in diabetic patients is indisputable, 
some T2DM patients with HbA1c below the diabetes definition threshold still develop 
microvascular complications40. This raises the question as to whether additional 
mechanisms might be involved in onset and disease progression of such 
complications41. Compelling evidence has suggested a role for methylglyoxal (MGO) 
as pivotal mediator of diabetic complications. In line with this, elevated levels of MGO 
in serum and tissues of patients with diabetes and ESRD have been reported 42,43. 
MGO is a reactive metabolite and a byproduct of carbohydrate, lipid and amino acid 
metabolisms. MGO reacts with proteins and nucleic acids causing protein 
malfunction and formation of advanced glycation end-products (AGEs)44.   
Exogenous administration of MGO in animals or in in vitro systems results in 
pathological changes seen in diabetic conditions such as microvascular damage and 
insulin resistance45–47. Compatible with this, is the remarkable finding that elevated 
levels of endogenous MGO in glyoxalase-1 (Glo-1) knockout drosophila is sufficient 
to recapitulate the phenotype of T2DM, namely obesity, insulin resistance and 
hyperglycemia41. Similarly,  knockdown of Glo-1 in a non-diabetic mice model, results 
in renal lesions similar to the ones found in diabetic mice models 48.  
MGO might also elicit an inflammatory response through the formation of reactive 
oxygen species (ROS). Pathological concentrations of MGO provoke a rapid 
production of ROS in human aortic endothelial cells49. In human vascular 
endothelium, MGO-induced inflammation is mediated via the activation COX-2, JNK 
and p38 MAP kinase50. At transcriptional level, MGO treatment elicits a strong 
upregulation of cell cycle arrest-associated genes, compatible with a possible 
activation of the p53 pathway51.   
During detoxification through the glyoxalase system, MGO reacts with reduced 
glutathione (GSH) and it is converted to S-D-lactoylglutathione52. The latter is further 
metabolized to lactate and GSH through the action of Glo-2. 
 
 Assessment of the GSH redox potential by GFP coupled- redox sensors  1.4
 
Under physiological conditions cells produce low amounts of ROS which are, 
amongst others, involved in modulating cell growth, differentiation, metabolism and 
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immune responses. Alterations in the cellular reduction-oxidation (redox) equilibrium 
are reflected by changes of the redox couples, i.e. reduced/oxidized thioredoxin and 
glutathione/glutathione disulfide (GSH/GSSG)53. The latter is considered to have a 
major role in maintaining intracellular redox equilibrium  and is the most important 
redox buffer in almost all eukaryotic cells54.  
 
Measurement and quantification of the cellular redox status with conventional tools 
often lack specificity for the redox pair in question and  usually require cell lysis which 
introduce oxidation artefacts in the system55. In recent years, genetically encoded 
fluorescent sensors appeared to overcome these limitations allowing real-time 
assessment of the intracellular redox status. These probes make use  of the green 
fluorescent protein (GFP) which has been widely used in biology for molecular 
labeling and protein tagging since its discovery in 196256. Wild type GFP has a single 
emission peak at 509 nm55, while it has two excitation peaks with a maximum at 395 
nm and 475 nm respectively. These correspond to the protonated-neutral and the 
deprotonated-anionic form of the chromophore. The dual excitation behavior can be 
exploited for radiometric measurements. One of the many advantages of the 
radiometric indicators is that it minimizes measurement errors resulting from changes 
in indicator concentrations, photobleaching, illumination stability and imaging 
artefacts54,55. 
Different indicators of the redox status such as roGFP1 and roGFP2 have been 
constructed by substitution of specific surface-exposed residues with cysteines in the 
β-barrel structure in close proximity to the chromophore of GFP53,54. Disulfide bonds 
between these cysteine residues promotes protonation of the chromophore and 
increases the excitation spectrum resulting in enhancement of GFP fluorescent 
properties53. 
 
RoGFP sensors report dynamic redox changes in response to a variety of exogenous 
membrane-permeable oxidizing and reducing agents. Typically, these responses 
have been described for incubation with H202 and dithiothreitol (DTT), however it is 
not sufficiently clear which endogenous redox pair interact with roGFP53,54. 
Furthermore, the use of roGFP sensors is also limited by their slow response to 
changes in the redox potential57. Based on these limitations, Gutscher et. al 
rationalized to equip the sensor with Glutaredoxin1 (Grx1)(Grx1-roGFP) which 
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specifically catalyzes the equilibrium between the two redox pairs 
roGFP2reduced/roGFP2oxidized and GSH/GSSG (Fig.1)
57.   
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1 RoGFP-Based sensors.  (A) roGFP contains cystein residues capable of forming a disulfide bond 
in response to changes in intracellular glutathione redox potential. The redox equilibrium of roGFP 
with the GSH/GSSG couple occurs through endogenous glutaredoxins and proceeds slowly. (B) The 
fusion of Grx1 to roGFP substantially improves specificity and reaction rate of thiol-disulfide 
exchange between roGFP dithiol and 2GSH/ GSSG couple. Adapted from Bhaskar et. al 58 . 
 
 
Upon an oxidative stressor, a cysteine residue of Grx1 specifically reacts with GSSG 
to form a Grx1-gluthatione disulfide intermediate which will react with one of the two 
thiols on roGFP. This reaction results in S-gluthationylation. In the last step, 
gluthationylated  roGFP re-arranges forming an internal disulfide bridge. When the 
oxidative event is removed, GSSG rapidly normalize resulting in the equilibrium of the 
thiol/disulfide cascade55 (Fig.1). Thus, the response of Grx1-roGFP is a dynamic 
probe which rapidly equilibrates with intracellular GSH/GSSG couple. This improved 
version of the sensor also allows the detection of short and long lived reflections of 
GSH. Consequently, the oxidation of Grx1-roGFP by GSSG is 100.000 times faster 
compared to uncoupled roGFP. 
 
 
 The carnosine-carnosinase system 1.5
1.5.1 Carnosine  
Carnosine is a natural occurring dipeptide, composed of β-alanine and L-histidine, 
and synthesized by the carnosine synthase (CARNS) enzyme59. In mammalian 
tissues, carnosine is widely distributed but predominantly found in the olfactory bulb 
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of the brain and in skeletal muscle. In the latter, carnosine can be found in relatively 
high concentrations (10- 40 mmol/ kg of dry tissue)60.   
Endowed by a plethora of biological properties carnosine has been subject in a wide 
range of scientific fields, particularly in the context of muscle physiology, metabolic 
disorders and oxidative stress conditions. 
Carnosine acts as a physiological buffer and this property is mostly attributed to its 
characteristic imidazole ring and its pKa (6.72) which is close to the physiological 
pH61. In muscle, carnosine plays an important role in the contractile function of 
skeletal fibers and calcium handling61. Furthermore, human studies have shown that 
the degree of blood acidosis during high-intensity exercise is alleviated, when muscle 
carnosine content is increased62. Thus, high carnosine concentrations in muscle 
appear to improve high intensity exercise performance 62. 
 
The beneficial effect of carnosine in metabolic diseases, e.g. diabetes and 
hyperlipidemia, is widely reported. In streptozotocin-induced diabetic rats carnosine 
supplementation reduced hyperglycemia and hyperlipidemia63. Similarly, glucose 
lowering effects and preservation of pancreatic β-cell mass were reported in 
carnosine-fed db/db diabetic mice64.  In BTBRob/ob mice, which develop advanced 
features of diabetic nephropathy, carnosine treatment attenuated albuminuria, 
reduced mesangial matrix expansion and improved other glomerular anomalies of 
diabetic nephropathy65. Furthermore, inhibition of pro-apoptotic signaling and 
podocyte loss were prevented by carnosine feeding in streptozotocin-diabetic 
induced rats66. Interestingly, in db/db mice carnosine appeared to accelerate wound 
healing and increased expression of growth factors and cytokine genes involved in 
reparative processes67. 
 
Numerous mechanisms may underlie the beneficial effect of carnosine to improve 
metabolic condition. Discussed are carnosine’s antioxidant properties, its ability to 
reverse protein glycation, and its ability to reduce AGE and advanced lipoxidation 
end-product (ALE)  formation. Carnosine’s antioxidant activity involves scavenging of 
reactive oxygen species (ROS) such as hydroxyl- and superoxide radicals, but also 
involves the upregulation of antioxidant enzymes 61. Accordingly, carnosine treatment 
was found to reduce markers of lipid oxidation and to restore the depleted levels of 
glutathione (GSH) and the basal activities of SOD and glutathione peroxidase (GPX) 
in the liver and heart of aged rats68. 
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The anti-glycating properties of carnosine have been repeatedly reported in vitro and 
in vivo.  Compelling evidence suggests that carnosine acts at different stages of 
AGEs formation, i.e. from reversing the formation of Schiff bases (first product of 
protein glycation) to reversal of preexisting glycated proteins69–71. Furthermore, 
carnosine reacts strongly with 4-hydroxy-trans-2,3-nonenal (4-HNE), the most 
abundant class of ALE precursors, and forms stable carnosine-HNE reaction 
adducts65,72,73. Since the production and accumulation of ALEs and AGEs are 
important mediators in diabetic complications, the use of carnosine has gained 
prominent scientific interest and numerous in vivo and vitro diabetes relevant studies 
have reported positive results to diminish or prevent diabetic associated 
complications. Furthermore, recent data from a clinical trial confirmed  to some extent  
carnosine beneficial effects in pre-diabetic obese patients74,75. 
 
1.5.2 Carnosinase 
 
Carnosinase (CN1), encoded by the CNDP1 gene, was first described by Teufel et. al 
as a dipeptidase belonging to the metalloproteases family. CN1 is the rate-limiting 
enzyme for the hydrolysis of carnosine into alanine and histidine, and also other 
histidine-containing peptides, i.e. anserine and homocarnosine 76. 
One of the first reports suggesting a link between DN and CN1 came from the finding 
that a trinucleotide repeat ((CTG)n) polymorphism in the CNDP1 gene was associated 
with susceptibility to develop DN. The finding showed that patients with T2DM and 
homozygous for the short allelic variant (CTG)5, also referred as the Mannheim allele,  
have a lower risk of developing DN.77. 
Thereafter, multiple studies have consistently confirmed the association between this 
polymorphism  and  susceptibility to develop DN in T2DM of different ethnicities 78,79. 
Interestingly, this association has been suggested to be sex-specific80. 
Nonetheless, it should also be mentioned that studies in patients of african-american 
and mexican-american ethnicity have failed to demonstrate this association. 81,82 
In patients with type 1 diabetes there are also inconsistent findings related to the 
association between CNDP1 and ESRD. While in a genome‐wide SNP genotyping 
approach in unrelated Caucasian individuals with type 1 diabetes an association 
between ESRD and CNDP1 was observed83, this was not found in another case-
control study of caucasian patients with type 1 diabetes84. Likewise, Alkhalaf et al. did 
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not find an association between the homozygous CNDP1(CTG)5 genotype and DN in 
patients with type 1 diabetes, but rather an increased risk for progression to ESRD 
late after baseline measurements85. 
The influence of the CNDP1 Mannheim allele has also been investigated in non-
diabetic nephropathies. Accordingly, studies have showed that the (CTG)5 is 
associated with a slower progression to CKD and to slightly correlate with renal 
survival in patients with glomerulopathies but not in patients with tubulointerstitial 
disease86,87. 
 
The (CTG)n polymorphism located within the signal sequence of the CNDP1 gene is 
functional as it influences the efficacy of CN1 secretion from the liver into the 
circulation88. The shortest allelic form (CTG)5, has been associated with low CN1 
enzymatic activities and serum concentrations which presumably allows higher tissue 
carnosine concentrations affording protection against hyperglycemia-mediated tissue 
damage 77,88 (Fig.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.2 Proposed link between the (CTG)5  in the CNDP1 gene and susceptibility  to develop diabetic 
nephropathy, adapted from Boldyrev et. al61.
Aim of the study  
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Apart from  hyperglycemia and the (CTG)n polymorphism, a recent study suggest that 
renal function might also influence CN1 concentrations in serum of patients with 
T2DM89. 
In rodents, CN1 is not a secreted protein and its expression is confined to the 
kidney76. Thus, it is important to underscore that extrapolation of findings from animal 
studies to humans is limited.   
In humans, the expression of CN1 is distributed among different tissues. Initially, 
CN1 expression was found in liver and brain and some years later it was reported in 
the kidney76,77,79,90. Accordingly, Janssen et.al showed an elevated expression in 
glomeruli of patients with DN and corroborative studies have also shown marked 
differences in renal CN1 expression between healthy subjects and patients with 
DN77,90. Peters et. al reported that CN1 is primary localized in the distal tubuli and 
glomeruli of healthy individuals, while in T2DM patients with DN the expression of 
CN1 is elevated and much more localized  to proximal tubuli90.  
 
  Aim of the study 1.6
 
In human both carnosine degrading and synthesizing enzymes, i.e. CN1 and 
Carnosine synthase (CARNS) are expressed in the kidney. While polymorphisms 
that are associated with the susceptibility to develop DN have been described for 
CN1, no such polymorphisms for CARNS have been reported. Therefore the studies 
performed in the first part of this doctoral thesis particularly focus on the role of CN1 
in the progression of DN. Since CN1 is expressed in the kidney and targeted to the 
secretory pathway we hypothesized that CN1 would be detected in urine as a 
consequence of renal secretion.  
In patients with DN, we expect that the extent of urinary CN1 would be increased as 
a consequence of impairment in the glomerular filtration barrier integrity. 
Because high renal CN1 concentrations may lead to depletion of renal carnosine 
stores which may have renoprotective properties in hyperglycemic conditions, we  
also expect an association between the extent of urinary CN1 and renal function 
deterioration.  
 
The following questions were addressed to test these hypotheses using well-defined 
patient cohorts: 
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1) Is CN1 found in urine of healthy individuals and in patients with DN? 
2) Is urinary CN1 associated with renal function deterioration? 
3) Is urinary CN1 inversely associated with serum CN1 concentrations? 
4) To what extent is urinary CN1 influenced by the CNDP1 (CTG)n 
polymorphism? 
Part of the results from this section have been published by Rodriguez-Niño A et al. 
in Amino Acids 51: 17–25, 2019 under the title “Detection of carnosinase-1 in urine of 
healthy individuals and patients with type 2 diabetes: correlation with albuminuria and 
renal function”. 
 
In the second part of the thesis we performed in vitro experiments to explore the 
toxicity of MGO towards vascular endothelial cells. We hypothesized that MGO 
causes structural damage to cultured endothelial cells and that this is ameliorated by 
carnosine. Because we also expect that MGO affects the redox status in cultured 
endothelial cells the properties of a roGFP-based redox sensor was tested with the 
aim to assess how MGO and carnosine affect the intracellular redox milieu in 
cultured endothelial cells. 
To this end the following questions were addressed: 
5) Does MGO affect viability of endothelial cells and is this counteracted by 
carnosine? 
6) Is toxicity by MGO related to DNA damage? 
7) How is the intracellular redox milieu changed upon MGO and carnosine?
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2 MATERIALS AND METHODS 
 Materials 2.1
2.1.1 Chemicals 
2.1.1.1 Comercial chemicals 
Table 2. Comercial chemicals 
 
 
Chemicals 
 
Source 
   
Acrylamide  40 %  Sigma-Aldrich (Germany) 
Agarose (PAGE)  Serva (Germany)  
Albumin standard (BSA)  Thermo Scientific™ (USA)  
Ampicillin  Bioline GmbH (Germany)  
APS  Sigma-Aldrich (Germany)  
Blue-White Select™ Screening Reagent  Sigma-Aldrich (Germany)  
BM blue, POD substrate, soluble  Roche (Germany)  
Carnosine (L-)  Sigma-Aldrich (Germany)  
CASY-ton  Roche (Germany)  
Chemiluminescence Reagent Western Lightning™  Perkin Elmer (USA)  
Collagen 0,1%  Sigma-Aldrich (Germany)  
Collagenase (from Clostridium histolyticum) Type V  Sigma-Aldrich (Germany)  
Coomassie Protein Assay Reagent  
DAPI 
Pierce (USA)  
Sigma-Aldrich (Germany) 
Deferoxamine  Sigma-Aldrich (Germany)  
DMEM/ high glucose, GlutaMAXGibco®  Thermo Scientific™ (USA) 
DMSO  
DnaseI recombinant 
Sigma-Aldrich (Germany) 
Invitrogen (Germany)   
DNA ladder buffer 10 x  Invitrogen (Germany)  
DNA ladder generuler 1kb  Invitrogen (Germany)  
D-PBS 1 x Gibco®  Invitrogen (Germany)  
DTT 0,1M  Invitrogen (Germany)  
Endothelial cell growth medium, advanced  Provitro (Germany)  
Ethanol 100%  Sigma-Aldrich (Germany)  
Fetal Calf Serum  
Gelatin from bovine skin  
PAA Laboratories (Austria)  
Fluka (Germany) 
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Hydrogen chloride 1M  
Hydrogen peroxide 30%  
Hydrogen sulfate (H2SO4)  
Sigma-Aldrich (Germany) 
Merck (Germany)  
Sigma-Aldrich (Germany)  
Isopropanol  
Laemmli-buffer  
LB Agar  
LB Broth Base (Lennox L Broth Base)®  
Magnesium chloride (MgCl2) 
2-β-Mercapto ethanol 
Metafectene® 
Methanol 
Merck (Germany)  
BioRad (USA)  
Sigma-Aldrich (Germany)  
Invitrogen (Germany)  
Fluka (Switzerland) 
Sigma-Aldrich (Germany)  
Biontex (Germany) 
Carl Roth (Germany) 
Milk powder Fluka (Switzerland) 
Na-butyrate Sigma-Aldrich( Germany) 
NaCl (sodium chloride) Merck (Germany)  
dNTP-Mix (dATP, dTTP, dCTP, dGTP) Carl Roth (Germany) 
PageRuler Plus Prestained Protein ladder Invitrogen (Germany)  
PBS 10x Invitrogen (Germany) 
Penicillin Sigma-Aldrich (Germany)  
Penicillin/streptomycin Sigma-Aldrich (Germany) 
Phosphatase Inhibitor Cocktail   Sigma-Aldrich (Germany) 
Poly-D-lysine hydrobromide 
Polybrene 
Protease Inhibitor Cocktail Tablets 
RNAse Inhibitor 
SDS 
Sigma-Aldrich (Germany) 
Sigma-Aldrich (Germany) 
Sigma-Aldrich (Germany) 
Roche (Germany) 
Carl Roth (Germany) 
TEMED Sigma-Aldrich (Germany) 
Tris/Glycine/SDS buffer 10× BioRad (USA) 
Trichloroacetic acid 
Tris-HCl, Trizma® hydrochloride 
TRIS buffer 1,5 M (pH =8.8)  
Triton® X-100  
TrypLETM Express  
 
Sigma-Aldrich (Germany) 
BioRad (USA) 
BioRad (USA) 
Carl Roth (Germany) 
Invitrogen (Germany) 
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Table 3. Chemical preparations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
 
              
Chemical preparations  
            
Ingredients 
 
 
APS (for WB) 
 
 
 
1g APS  
add to 10ml ddH2O  
 
Chamber buffer (for WB)  
 
 
Tris/Glycine/SDS buffer 10×  
1:10 diluted in ddH2O  
 
Lysis Buffer 
 
840 μl Lysis buffer Stock  
1 μl DTT  
10 μl Phosphatase Inhibitor  
150 μl Protease Inhibitor  
 
Loading buffer (for WB) 
 
950 μl Laemmli buffer  
50 μl β-mercapto ethanol  
 
Lysis buffer, stock solution  
 
 
10 mM Tris-HCl pH 7.4  
150 mM NaCl  
5 mM EDTA  
1 % Triton X-100  
0.5 % Na-Desoxychalat  
 
Lysis buffer, ready to use  
 
 
840 μl Lysis buffer Stock  
1 μl DTT  
10 μl Phosphatase Inhibitor  
150 μl Protease Inhibitor  
 
MTT  reagent 
 
5 mg / ml TBT in PBS  
 
MTT Solution 
  
 4 ml 10% SDS 
 4 ml DMSO   
 2 ml  PBS 
 1.2% ascetic acid  
 
0.1% PBST  (for WB and ELISA) 
 
 
1x PBS  
0.1% Tween20  
  
10 x TBS  
 
 
12.1g Tris Hcl  
87.66 g NaCl  
add to 1L ddH2O  
adjust pH value to 8.0  
 
10x Transfer buffer (for WB) 
 
30.3 g Tris,  
144.14 g Glycin,  
add to 1L ddH2O 
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2.1.2 Antibodies 
Table 4. Antibodies 
 
 
Antibody 
 
Source 
Dilution in 
WB 
Dilution in 
ELISA 
 
Anti-Human Carnosine Dipeptidase-1 
Affinity Purified Polyclonal Ab, Goat 
IgG (0.2mg/ml) 
 
 
R&D Systems 
(Minneapolis, USA) 
 
 
-------- 
 
1:200 
 
Anti-CNDP1 
 
 antibody produced in rabbit (ATLAS)   
polyclonal IgG 
(0.3 mg/ml) 
 
 
Sigma-Aldrich 
(Munich, Germany) 
 
1:1000 
 
1:600 
 
Goat anti-rabbit IgG HRP 
 
Santa cruz 
(Heidelberg,  
Germany) 
 
1:2000 
 
1:1000 
 
2.1.3 Restriction enzymes  
Table 5. Restriction enzymes 
 
                              Enzyme Source 
HindIII  ( for CN1-transgenic mice generation) New England BioLabs (Germany)  
 
Stu ( for CN1-transgenic mice generation) New England BioLabs (Germany)  
 
XbaI ( for roGFP) New England BioLabs (Germany)  
 
BamHI ( for roGFP)  New England BioLabs (Germany)  
 
 
 
  
 
Fixation solution (for TUNEL) 
 
4% paraformaldehyde in PBS  
Adjust Ph value to 7.4 
 
Permeabilization solution(for TUNEL) 
 
0.1% Triton X-100 in 0.1% sodium 
citrate 
 
 
DNAse I recombinant ( for TUNEL) 10µl  DNAse I (3000U/ml) 
10µ fetal calf serum 
1 ml 50Mm TRIS 
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2.1.4 Primers 
 
Table 6. Primers 
 
Primers Sequence (5 →3´) Tm 
(°C) 
GC Content       
(%) 
 
CN1 forward 
 
CCT CGC TTC AGA CAA GAG CTC TTC 
AGA ATG A 
 
62.4 
 
55 
CN1 reverse GCT CTG AAG GCG CTC ACA GCA TTG 
ATC CAA 
63.8 61.1 
 
 
 
2.1.5 Plasmids and vectors 
 
Table 7. Plasmids and vectors 
 
Plasmids and vectors Source 
 
pMD.G plasmid 
 
kindly offered by Dr. P. Pallavi (Department 
of Surgery, UMM)  
 
pCMV 8.91 plasmid kindly offered by Dr. P. Pallavi (Department 
of Surgery, UMM)  
 
Resen ( roGFP) Genewiz ( Germany) 
 
pPm337  vector Genewiz ( Germany) 
 
 
2.1.6  Kits 
 
Table 8. Kits used in experiments 
 
Kit Source 
 
DH5α E.coli 
 
Invitrogen (Germany) 
Dam- / dcm- Competent E.coli New England BioLabs (Germany)  
Pure Yield Maxi Prep system Promega ( Germany) 
Genomic DNA isolation kit  Promega (Germany)  
Rapid DNA Ligation Kit Roche (Germany)  
Invisorb spin tissue mini kit Stratec (Germany) 
In situ Cell Death Detection kit, AP Roche (Germany) 
GoTaq® DNA Polymerase Kit  Promega (Germany)  
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2.1.7 Consumables 
 
 
Table 9. Plastic and other consumables 
 
 
Consumables Source 
 
Cell culture flasks Falcon™ 25 cm2 / 75 cm2  
 
BD Biosciences (USA)  
Disposable cuvettes Eppendorf (Germany) 
Disposable pipette Falcon™ 1 ml/ 2 ml/ 5 ml/ 10 ml/ 25 ml BD Biosciences (USA)  
Disposable scalpel Feather® (Japan) 
Disposable syringes BD Biosciences (USA) 
EDTA-potassium-S-Monovette 2.6 ml Sarstedt (Germany) 
Serum- Monovette 7.5 ml Sarstedt (Germany 
ELISA, high-binding 96- well plates Greiner (Germany) 
Eppendorf Safe-lock Tubes 0.5 ml / 1.5 ml / 2 ml Eppendorf (Germany) 
Eppendorf epT.I.P.S 0.1-10 μl / 2-200 μl / 50-1000 μl Eppendorf (Germany) 
Falcon™ Tubes 15 ml / 50 ml BD Biosciences (USA) 
Flat bottom plates Falcon™ 6 / 12 / 24 / 96 well BD Biosciences (USA) 
Gel-Blotting-Paper (Filter paper) Whatman® (England) 
Millex®-HA Filter Unit, 33mm (for concentrating virus) Merck Millipore (Germany) 
Mr. Frosty  Freezing Container Nalgene™ Thermo Scientific™ (USA) 
MultiGuard barrier tips 0.1-10 μl / 2-200 μl / 50-1000 μl Sorenson Bioscience(USA) 
Parafilm® M Bemis® (USA) 
PCR-Tubes™ 0.2 ml BioRad (USA) 
Petri dishes Falcon™ BD Biosciences (USA) 
Polyethylen Film, Fisherbrand® Fisher Scientific (Germany) 
PVDF-Membrane Roche (Germany) 
Sterile filter (0.22 μm) Fisher Scientific (Germany) 
VIVASPIN 20 Sartorius stedim (Germany) 
 
 
 
2.1.8 Machines and softwares  
 
Table 10. Machines and softwares used for experiments 
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Machines and softwares Source 
 
3130 Genetic Analyzer 
 
Applied Biosystems® (USA)  
3130 Genetic Analyzer Data Collection Software v. 3.0  Applied Biosystems® (USA) 
ABI Prism DNA Analyzer 3100  Applied Biosystems® (USA) 
Autoclave Typ ELVC 5075  Systec GmbH (Germany)  
Bunsen burner Butane / Propan CV 470 Plus  Campinggaz® (Netherland)  
Cell counting CASY®  Schärfe Systems (Germany)  
CellF software  Olympus (Germany)  
Centrifugation Biofuge Pico/ Fresco/ Primo R  Heraeus (Germany)  
Centrifugation 5415/ 5417C  Eppendorf (Germany)  
DNA concentration tester (Infinite® 200 NanoQuant)  Tecan (Germany)  
DNA Sequencing Analysis Software 5.2  Applied Biosystems® (USA)  
Electrophoresis chamber SUB-CELL®-GT  Bio-Rad Laboratories (USA)  
Electrophoresis chamber for western blot  Bio-Rad Laboratories (USA)  
ELISA Absorption measurement  Tecan (Germany)  
GraphPad Prism 7.0  GraphPad Software, Inc (USA)  
Guava( easyCyte) Luminex( USA) 
FlowJo FlowJo(USA) 
Imaging system for blot  Biometra (Germany) 
Immunofluoerscence optical microscopy  Olympus (Germany)  
Impulse Sealer TEW (Taiwan)  
Incubator for Cell culture HERAcell 150i  Heraeus GmbH (Germany)  
Incubator for bacteria culture  Melag (Germany)  
Incubator and shaker Certomat® HK  Biotech International (Germany)  
Light microscope DMIL  Leica (Germany)  
Microwave oven  Sharp (USA)  
Multi-pipette  Eppendorf (Germany)  
Pipette  Eppendorf (Germany)  
Refrigerator 4 °C  Liebherr (Germany)  
Refrigerator -20 °C  Liebherr (Germany)  
Refrigerator -80 °C  Liebherr (Germany)  
Shaker Vortex-Genie 2  Scientific Industries (USA)  
Shaking Incubator Labnet ( England) 
Sterile working bench for bacteria culture  Clean Air Supplies (Germany)  
Sterile working bench for cell culture  Heraeus (Germany)  
Tecan Spark M10 with injector Tecan ( Germany) 
Materials and Methods  
24 
 
Thermoblock TechneDri-Block® DB-2D  Biostep GmbH (Germany)  
TransBlot turbo Bio-Rad Laboratories (USA)  
UV Light 312 nm and CCD camera System  Intas (Germany)  
Vacuum system for maxiprep  Promega (Germany)  
Vortex machine 120  Heidolph (Germany)  
Water bath Typ 3043   Köttermann (Germany)  
Weight balance  Sartorius (Germany)  
Western-Blot imaging system Chemismart 5100  PEQLAB (Germany)  
XL STAT Biomed  Addisoft (USA) 
 
 
 Methods 2.2
 
2.2.1 Participant recruitment and sampling 
 
Living kidney donors and patients with T2DM (DIALECT cohort) 
 
Participants:  
A total of 361 T2DM patients from the DIALECT cohort were included in this study.  
DIALECT is a prospective study of T2DM patients recruited in  ZTD(Ziekenhuisgroep 
Twente) a  secondary health care center in the Netherlands91. The study was 
approved by the local institutional review boards of the Netherlands (METc-
registration numbers NL57219.044.16 and 1009.68020) and is registered in the 
Netherlands Trial Register (NTR trial code 5855). Patients with type 2 diabetes older 
than 18 years old, able to understand the informant consent were eligible. Patients 
that underwent kidney transplantation or patients with dependency on renal 
replacement therapy were excluded. 
The living kidney donors patients (control group) consisted of 243 healthy individuals 
that were regularly checked for living kidney donation in the University Medical 
Center Groningen . None had medical history of diabetes, kidney or cardiovascular 
disease. The institutional board approved the study protocol (METc 2008/186). 
 
Sampling and definitions: 
For the 24-h urine collection, patients were instructed to dispose of the first morning 
void urine, and thereafter collect all urine in a provided container until the first urine of 
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the next day. Albuminuria, glycosuria and urinary CN1 excretion rates were 
calculated by multiplying concentrations with the volume of the 24-h urine collection.  
Normoalbuminuria was defined as 24-h urinary albumin excretion of <30mg/day. 
Micro and macroalbuminuria were defined as 24-h urinary albumin excretion of 30-
300 mg/day and >300 mg/day respectively. Estimated glomerular filtration rate 
(eGFR) was calculated according to CKD- EPI formula.  Tests for assessing HbA1c, 
serum creatinine and cholesterol were performed in venous blood.  
 
Mannheim cohort  
 
Participants:  
 
Patients were recruited in the Vth Medical Clinic and in the Dialysis Unit at the 
University Medical Centre Mannheim. A total of 111 patients were included in the 
study and allocated in 2 groups: i.e. patients with type 2 diabetes and chronic kidney 
disease (n=85) and non-diabetic patients with other causes of kidney injury (CKD) 
(n=26). For allocation in the T2DM group patients met the following criteria: diabetes 
mellitus known from medical history and/or diagnosed by HbA1c >6.5% levels or 
fasting glucose >126 mg/dl. 
Non-diabetic patients with CKD were included after screening of patient medical 
records, medications and laboratory testing for plasma glucose or HbA1c to exclude 
diabetes. All patients were sub grouped according to their kidney function and degree 
of albuminuria.   
 
Sampling and definitions:  
Persistent albumin excretion in at least 2 independent occasions of >200 mg/l or 
ACR ratio (albumin/creatinine ratio) >300 mg/g was considered as macroalbuminuria. 
Microalbuminuria and normoalbuminuria were defined as ACR: 30-300 mg/g and 
ACR<30 mg/g respectively in at least 2 independent occasions.  
Parameters including glycated hemoglobin (HbA1c) body mass index (BMI), serum 
creatinine, and albuminuria/creatinine ratio (ACR) were extracted from medical 
records.  Estimated glomerular filtration rate (eGFR) was calculated according to 
CKD- EPI formula. Patients that underwent kidney transplantation or patients without 
residual diuresis were excluded. Subjects with missing urine and blood sampling 
were also excluded. The healthy controls consisted of 25 adults (17 females and 8 
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males) members of our laboratory stuff or students that voluntary decided to 
participate. None of them had history of diabetes, cardiovascular or kidney disease.  
The study was approved by the ethical committee and relevant local institutional 
review boards (193/2001). All patients and healthy volunteers enrolled in the study 
gave their written informed consent.  
Spot urine samples were collected by spontaneous miction and stored in -20 until 
further analysis. For measurement of plasma carnosinase concentration and CNDP1 
genotyping, blood of the antecubital vein was withdrawn and stored in -20 until 
processing.  
All procedures performed in studies involving human participants were in accordance 
with the ethical standards of the institutional and national research committee and 
with the 1984 Helsinki declaration and its later amendments or comparable ethical 
standards 
 
2.2.2 ELISA assays 
 
CN1 concentrations in serum and urine were measured by ELISA as previously 
described by Adelman et.  al respectively 92. Briefly,  High-binding microtiter plates 
were coated overnight with 100 μl of goat polyclonal anti-human CN1 (10 μg/ml). The 
plates were extensively washed and incubated with 0.05% of dry milk powder to 
avoid unspecific binding. Serum samples were tested in a dilution of 1:100 or 1:200 
and urine samples were tested undiluted. Each sample was tested in duplicate. The 
plates were placed on a shaker for 1 hour and subsequently washed with 1x 
PBS/Tween. Thereafter, rabbit polyclonal antibody (ATLAS, Abcam plc, Cambridge, 
United Kingdom) was added for 1 hour followed by extensive washing. Goat anti-
rabbit IgG HRP-conjugated antibody was added for 30 min followed by extensive 
washing. Deep-blue peroxidase (POD) (Roche diagnostics, Mannheim, Germany) 
was used for color development and reaction was stopped after 15 min by the 
addition of 50 μl of 1 M H2SO4. The plates were directly read at 450 nm fluorescence. 
A serial dilution of pooled serum with a known concentration of carnosine (2µg/µl) 
was used as standard. CN1 protein concentrations were assessed in the linear part 
of the dilution curve with a lower detection limit of 31 ng/ml. Concentrations below the 
detection limit were considered as CN1 negative or cero. 
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2.2.3 CN1 enzymatic activities 
 
CN1 activities in urine and in recombinant protein were measured as described by 
Peters et al 2010. Briefly, reaction was initiated with addition of carnosine into the  
samples and stopped with 1% trichloroacetic acid at predetermined time points (0- 5-
15 and 30 minutes). Supernatants were taken after centrifugation and placed in a 
new tube in combination with o-Phthalaldehyde. Fluorescence liberated by histidine 
substrate was read using a Tecan plate reader (λExcitation: 360 nm; λEmission: 460 nm). 
 
2.2.4 Generation of hCN1 transgenic mice 
 
Briefly, the cDNA of human CN1 including the endogenous signal peptide of six 
leucines was amplified from IMAGE clone acc.no.BX094414 using the primers CN1 
forward 5'PCACCATGGATCCCAAACTCGGGA3' and CN1 reverse 
5'PTCAATGGAGCTGGGCCATCT3'. PCR product was ligated into the Stu1 site of 
plasmid pTTR1ExV3 which contains the transthyretin promoter and drives hCN1 
expression specifically within the liver and brain. After fragment digestion using 
HindIII, the purified fragment was injected into the pronuclei of the fertilized ovum of 
BTBR (Black and Tan, BRachyuric) female mouse (purchased from Jackson 
Laboratories, Bar Harbor, ME, USA). All animal procedures were approved by the 
Regierungspräsidium Karlsruhe (AZ 35-9185.81/G-116/14).   
 
2.2.5 DNA isolation and sampling for animal experiments 
 
DNA was isolated from mice tails by making use of the Invisorb spin tissue mini kit 
according to the manufacturer’s instructions. The transgene TTP-hCN1 mutation was 
genotyped by PCRs as described in  Sauerhöfer et. al 64. Mice were housed at 22° C 
in a 12h light/dark cycle and fed regular chow and water ad libitum.  At week 24 of 
age, blood samples were collected from the orbital plexus under anesthesia and 
serum was isolated by centrifugation. To obtain morning spot urine samples, animals 
were placed in metabolic cages at the beginning of the light cycle.  Samples were 
stored at -20 until further use. Serum and urinary CN1 concentrations were assessed 
with ELISA as previously described.  
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2.2.6 CNDP1 genotyping 
 
Animal experiments 
PCR assays were performed to ensure the integration of human CN1 gene. 
 
Briefly, PCR was performed using primers CN1 forward 
5'CCTCGCTTCAGACAAGAGCTCTTCAGAATGA3' and CN1 reverse 
5'GCTCTGAAGGCGCTCACAGCATTGATCCAA3' yielding a product of 343 base 
pairs. The PCR application program is depicted as follows: 
 
 
 
Human participants 
Genomic DNA was isolated from EDTA blood using the Genomic DNA isolation kit 
(Promega, Mannheim, Germany). A standard PCR protocol with the following 
fluorescence labeled forward primer: 5′-FAM-GCGGGGAGGGTGAGGAGAAC-3′ and 
unlabeled reverse primer 5′GGTAACAGACCTTCTTGAGGAATTTGG-3 was used.  
After PCR amplification, fragment analysis was performed with an ABI310 analyzer 
(Perkin Elmer) to determine the fragment length corresponding to the different 
genotypes. Each peak corresponded with the number of leucine repeats(CTG)n on 
each allele. The 157-, 160-, and 163-bp products corresponded with (CTG)5, (CTG)6, 
and (CTG)7  repeats, respectively. 
 
2.2.7 Protein precipitation and Westernblotting 
 
Qualitative detection of CN1 by Westernblotting was performed as previously 
described 92. Urine samples from healthy subjects were approximately 10x 
 T° Duration Step 
 
          1 
 
94 °C 
 
3 minutes 
 
2 94 °C 1 minute Denaturation 
3 60 °C 45 seconds Annealing 
4 72 °C 2 minutes Extension 
5 72°C 10 minutes  
6 4° C         ∞ End of cycle 
30 cycles 
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concentrated. Protein precipitation was performed by addition of 1 volume of 100% 
Trichloroacetic acid to 4 volumes of sample and supernatants were removed after 
centrifugation. Pellets were washed twice with 200 µl of cold acetone and let dry for 
10 minutes in 95°C heat block.  Pellets were dissolved in laemmli sample buffer 
containing β-mercaptoethanol  
and boiled for 20 minutes. Urine and serum samples were loaded on a 10% SDS-
PAGE gel and run at 180V for 1 hour. Proteins were transferred to a PVDF 
membrane by semi-dry blotting at 1A/25V for 30 mins. The membrane was blocked 
with 5% milk powder in 1% TBST for 1 hour and thereafter incubated with primary 
antibody diluted in 5% milk powder at 4°C overnight. Next day membrane was 
washed three times with TBST and incubated for 1 hour with the corresponding 
secondary antibody. After extensive washing detection of immune reactive bands 
was performed by enhanced luminol reagent and visualized by chemiluminescence.  
 
2.2.8 HUVECs isolation 
 
Fresh umbilical cords were obtained from the obstetric department of UMM. 
Permission to isolate endothelial cells form umbilical cords was granted by the 
medical ethics committee of the medical faculty Mannheim (AZ 2015-518N-MA).  
Human umbilical vein endothelial cells (HUVECs) were isolated by insertion and 
fixation with suture thread of glass tubes into both ends of the umbilical vein. The 
veins were flushed with 20ml PBS twice to remove erythrocytes. Thereafter, sterile 
collagenase solution (0.5mg/ml in PBS) was injected into the vein, followed by 12 
minutes of incubation in water bath at 37°C. The collagenase solution was 
transferred to a new 50ml falcon tube by flushing the vein with 20 ml of 10% FCS and 
PBS. The cells were centrifuged (300g, 5min), re-suspended in medium, and 
transferred to a previously coated-T25 flask.  
 
2.2.9 Cell Culture 
 
HUVECs were cultured in endothelial cell growth medium (Provitro, Berlin, Germany) 
containing 7.5% FCS and 50ng/ml amphotericin B together with 50μg/ml gentamicin 
37°C and 8% CO2. The flasks for HUVECs were coated in 1% gelatin 20 min before 
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use. All experiments involving HUVECs were performed in passages 2-6. HEK293 
and H1080 cells were cultured in DMEM high glucose GlutaMAX (Thermo fisher) 
containing 10% FCS and penicillin (100U/ml) / streptomycin (100μg/ml) in an 
incubator at 37°C and 5% CO2. 
 
2.2.10 Cell viability assay 
 
HUVECs were seeded at different densities in 96 well plates. Next day cells were 
challenged with different concentrations of Methylglyoxal for 24 hours and toxicity 
was assessed by MTT assay.  Briefly, 200µM thiazolyl blue tetrazolium bromide 
(5mg/ml in PBS) dissolved in cell medium (1:10) was added into each well.  Cells 
were placed in incubator at 37 °C for 4-5 hours.  Hereafter, crystals of formazan were 
dissolved by the addition of 100µM MTT solvent. The cells were incubated overnight 
at 37 °C. Absorbance was measured at a wavelength of 560 nm, using 670nm as a 
reference wavelength. Cell viability was calculated as percentage relative to 
untreated cells.  
 
2.2.11 DNA damage assay 
 
Following treatment with Methylglyoxal, cells were fixated with 4% paraformaldehyde 
and air dried for 1 hour. Thereafter, cells were incubated with permeabilisation 
solution for 2 minutes on ice and rinsed with PBS. To induce DNA strand breaks 
some cells were treated with DnaI recombinant (3000u/ml) for 10 minutes and used 
as a positive control. For the negative control only label solution was added.  
After drying, 50µL of TUNEL reaction mixture was added and cells were incubated 
for 1 hour at 37°C in a humidified atmosphere in the dark. Hereafter cells were rinsed 
with PBS and labeled with DAPI (1:5000) for 30 mins for nuclei visualization. After 
extensive washing cells were analyzed under fluorescence microscopy. 
 
2.2.12 Subcloning of roGFP and lentivirus production 
Contructs were designed by Dr. Prama Pallavi and synthesized by Genewitz (Clone 
ID B32523-1/q28382). The constructs were generated by fusing the coding 
sequences of human Grx1 with roGFP and thereafter subcloned into the pPM337 
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lentiviral vector.  For the production of lentivirus containing roGFP, HEK293T cells 
were transfected with a HIV-based 3-plasmid system (pCMV8.91, pMD.G and the 
plasmid containing roGFP). Supernatants were concentrated as viral particles. 
 
2.2.13 Lentivirus transduction and titration 
 
 Before vector infection of our target cells (HUVECs), transduction efficiency was 
examined by incubating HT1080 cells for 48 hours with different concentrations of 
lentiviral particles. Percentage of GFP positive cells was determined by FACS with 
Guava easyCyte using 488nm laser line for excitation and 525/30 nm filter set for 
emission. Data were analyzed using FlowJo software and used to calculate virus titer 
in each dilution. Cells were also visualized under fluorescence microscopy (10x) (Fig. 
3 A). HUVECs were transduced with different concentrations of lentiviral vector for 48 
hours and transduction efficiency was  assessed by visualization of GFP under 
fluorescence microscopy (40x) (Fig.3 B).  
Since in transduced HUVECs an optimal expression of GFP was observed at 1:100 
dilution, this lentiviral concentration was used in posterior experiments. The stability 
of the vector over passages was also verified by qualitative assessment of GFP 
under the florescence microscope.  Up to three passages after transduction no 
evident GFP expression changes were observed (data not shown). 
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Fig. 3 Transduction of cells with roGFP-containing lentiviral vector. (A) HT1080 cells were incubated 
with different concentrations (1:100 to 1.10.000) of lentiviral particles containing roGFP (GFP-
coupled redox sensor). Vector integration was assessed by FACS and fluorescence microscopy. At a 
1:100 dilution positivity of nearly all the cells (96.7%) by FACS analysis is observed. (B) HUVECs were 
incubated with 1:10 to 1:1000 dilution of lentiviral particles. Note that at 1:100 a strong positivity for 
GFP is observed under fluorescence microscopy, magnification (40x). 
 
2.2.14 Radiometric measurements 
 
RoGFP expressing cells were seeded in 96-well plate. Next day, prior to 
measurements  cell medium was exchange with PBS. We measured the emission of 
roGFP at 528nm after excitation at 395 and 485 nm in a plate reader set at 37°C 
(Tecan Spark M10) equipped with built-in injectors. 
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2.2.15 Statistical analysis 
 
Continuous variables were expressed as means ± SD or median and interquartile 
range (IQR). Categorical variables were expressed as numbers and percentages. 
For comparison of groups, independent two tailed Student’s t-test or ANOVA with 
Tukey´s were applied for continuous variables if normally distributed.  For data with 
skewed distribution Mann Whitney-U or Kruskall-Wallis test with Dunn´s test were 
applied. For the analysis of categorical variables Fisher´s test or chi2 with bonferroni 
correction (based on the number of comparisons) were applied.  
Variables with skewed distribution i.e. urinary CN1, serum CN1, glycosuria and 
albumin/creatinine ratio (ACR) were log-transformed and correlations with other 
continuous variables were assessed using Pearson correlation test. 
Backward and Forward stepwise regression analysis were employed with log-
transformed urinary CN1+1 as a dependent variable to determine the best 
multivariate model predicting urinary CN1 concentrations. All statistical tests were 
two-sided and a p value <0.05 was considered statistically significant in all analyses. 
The analyses were assessed with Graph Pad Prism version 7.02 and XLSTAT
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3 RESULTS 
 Detection of Carnosinase1 in urine 3.1
Carnosinase1 (CN1) is predominantly produced by the brain and by the liver from 
where it is secreted into the circulation. Based on recent findings suggesting that 
CN1 is expressed in human kidney and that the signal peptide within CN1 enables its 
secretion, this study was carried out to assess whether CN1 can be detected in urine.   
Firstly, we assessed whether our in-house developed ELISA system used for CN1 
detection in serum or plasma was also suitable for the detection of CN1 in urine 
samples. To this end, serial dilutions of known concentrations of CN1 recombinant 
protein (rCN1) were made in spot urine samples from healthy individuals or in 
standard diluent (phosphate buffer saline) respectively. 
The spike-recovery of the assay was calculated by comparing the detected and 
expected concentrations of rCN1 in the different dilution points. Optimal spike 
recoveries were observed for both matrices with an average spike recovery of 109% 
which is within the acceptance range (80-120%) and suggests that urine matrix 
components do not interfere with or inhibit CN1 detection.  The detection range of the 
ELISA was 31 ng/ ml up to 2000 ng/ml and  linearity of the curves was observed in a 
concentration range of 100 to 1000 ng/ml (rCN1 spiked in urine :R2 =0.99 ; rCN1 
spiked in PBS: R2 =0.97) (Fig.4A) 
The specificity of the in-house developed ELISA system was assessed by testing 
urine and serum samples of mice overexpressing human CN1 (hCN1 transgenic 
mice) and wild type mice. 
 As depicted in Fig. 4B, CN1 was exclusively detected in mice overexpressing the 
hCN1 transgene and was undetectable in wild type mice. The presence of CN1 in 
serum and urine from mice was further verified by Westernblotting (Fig.4C and 4D) 
To further characterize the presence of CN1 in urine we assessed whether naturally 
occurring CN1 in human urine has any enzymatic activity.  
Although no enzymatic activity was detected in any human urine sample or in urine 
from CN1 transgenic mice, the addition of rCN1 to human urine resulted in 
measurable activities nearly comparable to that of rCN1 in standard assay buffer 
(Fig.4E).  
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Fig.4  Detection of CN1   (A) Recombinant CN1 (rCN1) was spiked in human urine or standard diluent 
(PBS). CN1 was detected by ELISA in serial dilutions using urine or PBS as diluent. (B) Specificity of the 
ELISA system: CN1 concentrations in serum (right y axis) and in urine (left y axis) of transgenic mice 
overexpressing human CN1 (TG CN1+) (n=9) and wild type mice (WT) (n=9). Representative 
Westernblotting of CN1 in serum (C) and urine (D) from transgenic CN1+ and wild type mice. (E) 
Human urinary CN1 displays no enzymatic activity whereas enzymatic activity of rCN1 spiked in 
human urine is measurable. Enzyme activity was measure as degradation of carnosine and derivation 
of the free amino acids as described in the methods. 
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 Characterization of 24h urinary CN1 in living kidney donors and T2DM 3.2
patients  (DIALECT cohort) 
 
During the validation of the ELISA system, we noticed that the blanks, i.e., urine 
without spiked CN1, showed traces of CN1 in the samples of some individuals. To 
substantiate these findings and to assess to what extended CN1 is detected in urine, 
24h urine samples of living kidney donors (n= 243) and patients with T2DM (n = 361) 
were collected and screened for CN1. Demographic characteristics of T2DM stratified 
by albuminuria excretion rate into normoalbuminuria (albuminuria>30 mg/24h) 
(n=241), microalbuminuria (albuminuria 30-300 mg/24h) (n=80) and 
macroalbuminuria (albuminuria >300 mg/24h) (n=40) are displayed in Table1. 
 
Table 11. Demographic and clinical characteristics of T2DM related to 
albuminuria. 
 
 
  T2DM   
 
Normo-     Micro- Macro- 
albuminuria albuminuria albuminuria 
 
Characteristics n = 241 n=80 n= 40 
   p 
value 
Demographic       
 
Men, n(%) 118(49) 56(70)
#
 31(78)
# $
 0.016 
Age (years) 62.8 ± 8.8 63.6 ±9.0 67.5 ± 7.9
#
 0.007 
Clinical        
 
SBP (mm Hg) 134.6 ± 15.3 139.4 ± 16.8 140.3 ± 19.4
#
 0.002 
DBP (mm Hg) 74.1 ± 9.0 75.3 ± 10.3 75.2 ± 10.8 0.55 
Body mass Index (kg/m
2
) 32.7 ±6.0 33.0 ± 5.7 32.8 ± 6.1 0.75 
Duration of diabetes (years) 11[6 - 18]            12[6 -18]                 10[6 -19] 0.65 
Retinopathy, n(%)  55(22) 26(33)    11(28) 0.21 
HbA1c (%) 7.3 ± 1.0 7.6 ± 1.2     7.2 ± 1 0.16 
Kidney Function       
 
Serum creatinine (mg/dl) 0.9 ± 0.3 1.1 ± 0.6
#
 1.4 ± 0.5
#$
 <0.0001 
eGFR (ml/min/ 1.73 m2) 81 ± 22 75 ± 26 54 ± 22
#$
 <0.0001 
Urine Osmolarity (mOsm/kg) 486.8 ± 210.0 494.6 ± 217.9 415.0 ± 170.4 0.10 
Urine Volume (ml) 2024 ± 783 2071 ± 775 2153 ± 961 0.48 
Glycosuria (mg/24 h) 451[85- 5263] 1137[105 – 8393]    326[74 – 4349] 0.17 
Albuminuria (mg/24 h) 4.4[1.5 – 11.1] 82.4 [59.6 –145.8]
#
     508.0[365.4 – 900.1]
#$
 <0.0001 
ACEi/ARB, n(%)  158(63.5) 57(71.4) 34(85)
#
 0.016 
 
p values were calculated using one-way ANOVA, Kruskall Wallis or Chi2 with Bonferroni correction. 
 #: compared to patients with normoalbuminuria, $: compared to patients with microalbuminuria. 
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In the group of patients with macroalbuminuria, the proportion of males was higher. 
The patients in this group were also older, showed higher levels of systolic blood 
pressure, higher serum creatinine concentrations and lower eGFR in comparison to   
patients with normo- and microalbuminuria. Additionally, a higher proportion of 
patients on ACEi/ARB therapy were found in the macroalbuminuric group compared 
to the other two groups (Table. 11).  
The proportion of CN1 detected in urine samples of macroalbuminuric patients was 
significantly higher (39 of 40) compared to the groups with microalbuminuria (65 of 
80) and normoalbuminuria (147 of 241) (97% vs 81% vs 63.5%, p=0.016) (Fig.5 A). 
In the healthy group, urinary CN1 was detected in 180 of 243 subjects (74%) (data 
not shown) The presence of CN1 in urine from T2DM patients and living kidney 
donors was qualitatively assessed by Westernblotting. (Fig. 5 B and 5 C)  
The median urinary CN1 excretion rates were significantly higher in patients with 
macroalbuminuria when compared to the micro- and normoalbuminuria groups (1.5 
mg/24h [IQR, 0.5 – 3.8 mg/24h] vs 0.2 mg/24h [IQR, 0.08 – 0.8 mg/24h] vs 0.1 
mg/24h [IQR, 0 – 0.4 mg/24h]; p <0.0001). Likewise, microalbuminuric patients 
displayed higher CN1 excretion rates in comparison to the group with 
normoalbuminuria (p<0.05) (Fig. 5 D).  
In the living kidney donors median CN1 excretion rates were: 0.2 mg/24h [IQR, 0 – 
0.6 mg/24h] and compared to T2DM patients significant differences were only found 
with the macroalbuminuric group. (p<0.0001) (Fig. 5 D). 
To better understand the relation between urinary CN1 and renal function, we looked 
at urinary CN1 concentrations in T2DM patients stratified on the basis of estimated 
glomerular filtration rate(eGFR) in <30, 30-60 and >60 ml/min/1.73m2. As depicted in 
Fig.5 E, patients with severely impaired renal function (<30 ml/min/1.73m2) appeared 
to have higher concentrations of urinary CN1 concentration in comparison to patients 
with preserved renal function (>60 ml/min/1.73m2). 
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Fig.5  (A) Proportion of urinary CN1 detection in T2DM patients stratified according to normo-micro- 
and macroalbuminuria. (B) Westernblotting of CN1 in urine obtained from 2 diabetic patients with 
macroalbuminuria. Positive control: urine from CN1+ transgenic mouse. The samples were loaded 
without prior concentrating of the urine. (C) Detection of CN1 in 10x concentrated urine from 3 
healthy individuals by Western Blotting. The bands are in concordance to the molecular weight of 
monomeric CN1. (D) Distribution of urinary CN1 concentrations in T2DM stratified according to 
albuminuria and in healthy subjects. (E) Distribution of urinary CN1 in T2DM according to eGFR. 
Patients were stratified into those with impaired (eGFR<30 ml/min/1.73m2) (n=13), intermediate 
(eGFR 30-60 ml/min/1.73m2) (n=74) and preserved renal function (eGFR >60 ml/min/1.73m2) (n= 
273): Boxes and whiskers represent the median and IQR. Outliers are indicated by circles. * p<0.05, 
** p<0.0001.  
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To investigate the association of urinary CN1 with clinically relevant parameters in 
diabetes we performed correlation analyses. In line with the aforementioned results, 
urine CN1 excretion rates were found to be positively and significantly associated 
with albuminuria (r =0.59, p<0.0001) (Fig.6 A). There was a modest negative 
correlation between CN1 excretion rates and eGFR (r = -0.24, p<0.0001) (Fig. 6 B).  
Additionally, there was a significant, albeit week positive correlation between urinary 
CN1 excretion rates and glycosuria (r=0.13, p=0.017) (Fig. 6 C). 
 
 
 
Fig.6 Significant correlations between urinary CN1 and clinical parameters in T2DM patients.  
(A) Positive correlation between urinary CN1 (log (urinary CN1+1)) and albuminuria, (B) Inverse 
correlation between urinary CN1 (Log (urinary CN1+1)) and eGFR.  Positive correlation between 
urinary CN1 (Log (urinary CN1+1)) and glycosuria 
 
 
 
In order to assess the independent influence of these factors on urinary CN1 a 
backward stepwise multivariate linear regression analysis was conducted. Urinary 
CN1 excretion rate was set as the dependent variable and its values were log 
transformed due to a skewed distribution (Log CN1+1). As shown in Table 12., 
albuminuria, eGFR, and glycosuria, appeared to be the best explanatory factors of 
Log CN1 excretion rates. All together, these parameters explain 37% of changes in 
urinary CN1 excretion rates (R2 = 0.37; p< 0.0001).    
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Table 12.  Multivariate linear regression analysis in T2DM patients 
 
Variables predicting urinary CN1 excretion rates (log (urinary CN1+1)) in patients with T2DM. 
Goodness of fit of the full model: R2= 0.37, p<0. 0001, CI: confidence interval. 
 
 
 Association of serum CN1 and CNDP1 genotype with urinary CN1 in patients 3.3
with T2DM and non-diabetic CKD.   
 
Although 24h urine collection has been considered the gold standard for the 
assessment of albuminuria, it is not routinely performed since it can be time-
consuming and often inaccurate due to frequent collection errors. Hence, in large 
cohorts and biorepositories mostly spot urine samples are collected. Based on this, 
we assessed if urinary CN1 can also be reliably detected in spot urine and if so, to 
confirm its association with renal function and albuminuria. Additionally, we examined 
whether the (CTG)5 polymorphism within the CNDP1 gene influences urinary CN1 
concentrations.   
To this end, CN1 metabolism, i.e. CN1 in serum, CN1 in spot urine and CNDP1 
(CTG)n genotype was studied in healthy subjects (n=25), patients with T2DM (n= 85) 
and in patients with CKD of non-diabetic etiology (CKD) (n=26). The baseline 
characteristics of T2DM and CKD stratified by microalbuminuria (ACR≤300 mg/gr) 
and macroalbuminuria (ACR>300 mg/gr) and the healthy subjects are depicted in 
Table 13. 
T2DM Patients with macroalbuminuria (ACR>300mg/gr) showed higher diabetic 
retinopathy frequencies, higher serum creatinine and lower eGFR levels compared to 
T2DM patients with microalbuminuria (ACR≤300mg/gr). CKD patients with 
macroalbuminuria displayed increased serum creatinine and low eGFR levels in 
comparison to CKD patients with microalbuminuria but these did not reach statistical 
significance (Table 13). The main causes of CKD of non-diabetic etiology were Ig-A 
nephropathy, focal glomerular sclerosis and glomerulonephritis. 
 
Predictive Parameter Beta Value 95% CI p value 
eGFR(ml/min) -0.001  -0.002 – -0.00015 0.019 
Log (glycosuria excretion + 1) 0.014 0.016 – 0.048 0.0007 
Albuminuria (mg/24 h) 0.0004 0.0004 – 0.0005 < 0.0001 
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Noteworthy, in the overall patient cohort (T2DM and non-diabetic CKD) (n=111), only 
18% of the patients had normoalbuminuria (ACR<30 mg/gr), less than 14% (16 of 
111) of patients showed eGFR above 60 ml/min/1.73m2 and 41% (46 of 111) were on 
renal replacement therapy. These characteristics reflect a population with 
predominant kidney impairment.  
The healthy control group consisted of 25 healthy adults without clinical signs or 
medical history of renal disease or diabetes. In this group there were more females 
(68%) than males and they were significantly younger (mean: 30 ± 9.3 years) 
compared to both disease groups (p<0.0001) (Table 13.).  
 
Urinary CN1 was detected in 95% of T2DM patients with macroalbuminuria and in 
48% of patients with microalbuminuria (p<0.0001). Likewise, the proportion of CN1 
detection in urine from CKD patients with macroalbuminuria was higher compared to 
the CKD group with microalbuminuria (88% vs 33%; p=0.0007) (Table 13.). In the 
healthy group, CN1 in spot urine was detected in 18 of 25 subjects (72%)(Table 13.). 
 
The concentrations of urinary CN1 were higher in macroalbuminuric in comparison to 
microalbuminuric patients irrespective of the baseline disease (T2DM: 554 ng/ml 
[IQR 212-934 ng/ml] vs 0 ng/ml [IQR 0-63.5 ng/ml] p<0.0001; CKD: 197.1 ng/ml [IQR 
112.1-738.5] vs 0 ng/ml [IQR 0-226 ng/ml] p=0.015) (Fig. 7 A). In the healthy group 
median urinary CN1 concentrations were: 77 ng/ml [IQR 0- 118.5] and were 
significantly lower compared to T2DM (p<0.0001) and CKD patients with 
macroalbuminuria (p=0.004) (Fig. 7 A). In line with these findings, a positive 
correlation between albuminuria (ACR) and urinary CN1 concentrations was found in 
the overall cohort of patients (r =0.66, p<0.0001) (n=111) (Fig. 7 B). 
Furthermore, when patients were stratified on the basis of renal function into eGFR 
<60 vs. eGFR >60 ml/min/1.73m2, significantly higher urinary CN1 concentrations 
were found in patients of the lower eGFR strata (p<0.05) (Fig. 7 C) 
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Fig. 7 (A) Distribution of CN1 in spot urine of T2DM and non-diabetic patients (CKD) with 
microalbuminuria (ACR≤300mg/g) and macroalbuminuria (ACR>300 mg/g) and healthy subjects. 
Results are expressed for each individual patient. The lines represent the median and IQR. (B) 
Pearson correlation between ACR (Log (ACR)) and urinary CN1 concentrations (Log (urinary CN1+1) in 
patients with T2DM and in non-diabetic patients (n=111). (C) Distribution of urinary CN1 
concentrations in all patients according to eGFR. T2DM and CKD patients (n=111) were stratified 
according to poor (eGFR <60 ml/min/1.73m2) (n= 95) and preserved renal function (eGFR >60 
ml/min/1.73m2) (n= 16). Boxes and whiskers represent the median and IQR. Outliers are indicated 
with circles. 
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       T2DM   CKD    
Healthy         
subjects 
  
ACR<300 mg/g ACR≥300mg/g   ACR<300 mg/g ACR≥300 mg/g   
 
Characteristics n= 44 n=41     p value n=9  n=17 p value  n=25 
              
 
Demographic              
 
Male sex n (%) 27(61) 30(73) 0.24 7 (78) 9(53) 0.39 8(32) 
Age(years) 68.3 ± 15.1 62.4 ± 15 0.06 70 ± 16.3 65.8 ± 17.9 0.61 30 ± 9.3 
Clinical  
      
  
Body mass Index(kg/m
2
) 31.3 ± 7.3 30 ± 6.3 0.28 28 ± 3.9 29 ± 6.8 0.68   
Hba1c (%) 8.2± 2.4 7.6 ± 2.0 0.22 5.1 ± 0.5 5.4 ± 0.8 0.31   
Serum Albumin(gr/l) 28.7±7.5 27.8±6.6 0.56 29.2±4.7 29±5.9 0.93   
FPG (mg/dl) 154.5± 66.2 145± 64 0.50 96.3 ±10.3 90 ±11 0.15   
Systolic BP(mmHg) 134.3 ± 22.4 142.5 ± 16.8 0.06 131.2 ± 26.2 137.7 ±19.4 0.48   
Diastolic BP(mmHg) 74.1±13.1 75.3±15.1 0.72 72±13 76.3±15.8 0.50   
Diabetic Retinopathy n(%) 19(43) 31(75) 0.004 - - 
 
  
Kidney Function 
      
  
Serum creatinine(mg/dl) 2.5 ± 1.7 4.7 ± 3.3 0.002 3.8 ± 2.0 4.4 ± 3.1 0.58   
eGFR(ml/min/1.73m
2
) 33 [17 - 60] 13 [7.5 – 30] 0.0005 12.6[8.3 – 49.4] 11.9[7.9 - 32] 0.80   
Albuminuria ACR(mg/g) 49.5 [13.3 -112] 1498 [580 - 3261] <0.0001 127 [31 – 207.5] 1150 [641.5-2099] <0.0001   
Dialysis n(%) 13 (30) 20 (49) 0.08 4 (44) 9 (53) 0.68   
   - Hemodialysis n(%) 12 18 
 
4 9 
 
  
   - Peritoneal dialysis n(%) 1 2 
 
- - 
 
  
Residual diuresis(ml/24h) 1600 [850-2500] 1000[650-2000] 0.09 1500[750-2000] 1500[1000-1572] 0.97   
Pharmacological  management 
      
  
ACEi/ARB n(%) 25(57) 25(61) 0.70 4(44) 9(53) 0.68   
Diuretic n(%) 30(68) 29(71) 0.80 7(78) 12(71) 0.69   
CN1  metabolism 
      
  
CN1 in serum (μg/ml) 3.9 [2.1 – 12] 4.6 [2.6 – 12.2] 0.74 3.0 [1 - 4.6] 3.9 [0.9 -6.3] 0.70 9.3 [5 – 22.2] 
 Urinary CN1 detection n(%) 22(48) 39(95) <0.0001 3(33) 15(88) 0.007 18(72) 
 Homozygous(CTG)5 n(%)*   15 (37) 11 (28) 0.48 3 (43) 3 (18)      0.31 7(28) 
Table 13. Demographic and clinical characteristics of T2DM and non-diabetic CKD related to ACR and healthy subjects 
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Based on the observations that urinary CN1 concentrations were increased in 
macroalbuminuric patients regardless of the baseline disease (T2DM or CKD) and 
that urinary CN1 positively correlates with ACR, we assessed whether serum CN1 
concentrations were decreased in these patients. To test this, all patients (n=111) 
were stratified on the basis of ACR in micro- (ACR≤300 mg/mg (n=53)) and 
macroalbuminuria (ACR>300 mg/mg (n=58)). 
Although no differences in serum CN1 concentrations were found between micro and 
macroalbuminuric patients (Fig. 8 A), significantly lower serum CN1 levels were 
observed in all patients (n=111) when compared to the healthy subjects (4.1 µg/ml 
[IQR 2.1-10.5 µg/ml versus 9.3 µg/ml [IQR 5.0 -22.2 µg/ml], p=0.0012) (Fig. 8 B). 
These differences were not attributed to differences in genotype distribution (the 
(CTG)5 homozygous vs. all other genotypes) as this was similar in both groups 
(healthy controls(72%) vs all patients (69%)( p> 0.05)) (Fig. 8 C), but might rely on 
the higher proportion of females included in the healthy group (Fig. 8 D). 
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Fig.8 (A) Distribution of serum CN1 concentrations in the studied patients (n=111) according to ACR 
in: microalbuminuria (ACR≤300 mg/g) (n=53) and macroalbuminuria (ACR>300 mg/g) (n=56). Boxes 
and whiskers represent the median and IQR. (B) The patient´s cohort display lower serum CN1 
concentrations in comparison to healthy subjects. (C) Differences are not related to the distribution 
of the homozygous CNDP1 (CTG)5 versus all other genotypes >(CTG)5 (p=ns). (D) The frequency of 
female distribution is higher in the healthy group (68%) in comparison to the patient´s cohort (35%) 
(p=0.0031) 
 
 
Interestingly, a modest but significant positive correlation between serum CN1 and 
urinary CN1 concentrations was observed for the whole cohort of patients (n=111) 
(r =0.22, p=0.018) (Fig. 9 A). 
Since the (CTG)n polymorphism within the CNDP1 gene is known to influence CN1 
concentrations in serum, we investigated whether this was also true for urinary CN1 
concentrations. To test this, serum and urinary CN1 concentrations from healthy 
subjects and T2DM were stratified for genotype into (CTG)5 homozygous versus 
other genotypes (>(CTG)5). Whereas healthy subjects homozygous for (CTG)5 
showed significant lower serum CN1 concentrations  compared to  healthy subjects 
carrying other CNDP1 genotypes (5.5 µg/ml [IQR 3.2 – 9.1] versus 11.5 µg/ml[IQR 
5.5-31.1]; p= 0.017), no differences in urinary CN1 concentrations in (CTG)5 vs 
>(CTG)5  were  found  (81.3 ng/ml [IQR 0 - 146] vs 76.6 ng/ml[IQR 0 - 115.2]; p=0.83)  
(Fig. 9 B). In T2DM patients, a trend towards lower median serum and urinary CN1 
concentrations in the (CTG)5 homozygous group compared to >(CTG)5  was observed 
but did not reach statistical significance (in serum: 3.5 µg/ml[IQR 1.9 - 10.9] versus 
4.4 µg/ml[IQR 2.6 - 12.7], p=0.62 and in urine: 59.6 ng/ml[IQR 0- 503.2] vs 141.3 
ng/ml [IQR 26.1- 718.5]; p= 0.14 respectively) (Fig. 9 C).  
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Fig.9 (A) Pearson correlation of serum CN1 (Log (Serum CN1 +1)) and urinary CN1 (Log (urinary 
CN1+1)) concentrations in all patients (n=111).  (B and C) Distribution of serum CN1 (left y axis) and 
urinary CN1 concentrations (right y axis) according to CNDP1 genotype ((CTG)5 homozygous versus 
other CNDP1 genotypes >(CTG)5)  in healthy subjects (B) and in patients with T2DM (C). Results are 
expressed for each individual patient. The lines represents the median and IQR. 
 
To gain more insight into the factors influencing urinary CN1 concentrations in the 
overall patient cohort (n=111), relevant kidney disease-associated variables i.e. age, 
sex, baseline kidney disease (T2DM or non-diabetic CKD), renal replacement 
therapy, serum CN1 concentrations, CNDP1(CTG)5 homozygosity, eGFR and ACR 
were selected as independent predictors of log-transformed (urinary CN1 +1) (Table 
14.). In univariate analysis, the variables sex, baseline disease and renal 
replacement therapy did not reach the significance threshold and were excluded in 
the subsequent multivariate model. The remaining variables with a p value <0.25 
were included in the multivariate linear regression model (Table 14.). Multivariate 
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analysis revealed that albuminuria (ACR) and serum CN1 concentrations are the 
strongest predictors of urinary CN1 concentrations, all together explaining 44% of 
variation of urinary CN1 concentrations (log urinary CN1 +1) (R2 = 0.44, p< 0.0001). 
 
 
Table 14. Univariate and multivariate analysis of urinary CN1 in T2DM and CKD 
patients 
 
Univariate and multivariate regression models with log transformed (urinary CN1 +1) as the 
dependent variable. Goodness of fit of the multivariate regression full model: R2= 0.44; p<0. 0001 
 
 Toxicity profile of Methylglyoxal in human vascular endothelium 3.4
 
Methylglyoxal (MGO) is a reactive carbonyl species (RCS) mainly derived from 
glucose metabolism. Diabetes is associated with increased levels of RCS, which are 
believed to be implicated in the development of micro and macrovascular 
complications in these patients. In this section we investigated the susceptibility of 
human umbilical vein endothelial cells to MGO. To this end, HUVECs were treated 
with a wide range of MGO concentrations (100, 200, 400 and 800 µM) over a period 
of 24 hours. Changes in cell morphology and impairment of cell viability were 
assessed by microscopy and MTT assay respectively. As depicted in Fig.10 A, cell 
detachment was already evident at 400 µM of MGO and became worse at and 800 
µM. These changes were associated with a significant decrease of cell viability as 
assessed by MTT (Fig. 10 B). Toxicity towards 800 µM of MGO was clearly 
dependent on the number of seeded cells, with lower numbers of seeded cells being 
more susceptible to MGO (Fig. 10 C).   
                        Univariate analysis            Multivariate analysis 
Variable Coefficient (β)           95% CI p-value    Coefficient (β)     95% CI   p-value 
Age (years)  -0.012  -0.028  - 0.003  0.11   0.003 -0.01 0.02 0.68 
Female sex   -0.270  -0.76 0.22 0.27    -          -  - 
non-diabetic kidney disease 0.150  -0.407 0.706 0.57    -         -  - 
On renal replacement therapy  -0.195  -0.70 0.28 0.41    -         -  - 
 CNDP1 (CTG)5 homozygosity  -0.500  -0.9 0.001 0.050    -0.21  -0.61 0.18 0.29 
Log ( Serum CN1 +1) 0.605 0.093 1.118 0.021   0.65 0.25 0.04 0.002 
Log (ACR) 0.630 0.48 0.79 <0.0001   0.89 0.65 1.13 <0.001 
eGFR(ml/min/1.73 m
2
)  -0.009  -0.017  -0.0003 0.042   0.001  -0.01 0.01 0.88 
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                     A 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10.  Cytotoxicity of methylglyoxal after 24 hours. HUVECs were treated with different 
concentrations of MGO for 24 hours. Changes in cell morphology and cell viability were assessed by 
phase-contrast microscopy and MTT assay respectively. (A) Representative pictures of HUVECs 
treated with different concentrations of MGO. Original magnification 10x (B) Cells were seeded at a 
density of 25.000 cell/well and viability was measured by MTT and expressed as % of control cells not 
treated with MGO. Cell viability strongly decreased at 400µM and 800µM MGO **p<0.0001 
compared to control (0 µM MGO). For each condition 6 replicates were used.  (C) Toxicity towards 
800 µM of MGO was tested against different densities of seeded cells (10.000, 25.000 and 50.000 
cells/well). Note that at the highest cell density (50.000 cells/well) cell viability is no longer affected 
by 800 µM MGO.  
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To investigate if MGO-mediated toxicity was associated with DNA damage and cell 
apoptosis, TUNEL assay was performed. As depicted in Fig. 11, at concentrations of 
800µM MGO an evident increased number of TUNEL positive cells were observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 11.  MGO treatment induces apoptosis. HUVECs were treated for 24 hours with 400 or 800µM 
of MGO and detection of apoptotic cells was assessed by TUNEL assay. Medium: untreated cells, 
Dnase I treatment: Positive control. Magnification: 20x. 
 
 
 Carnosine treatment ameliorates MGO-induced toxicity 3.5
 
Based on the alleged anti-oxidative and RCS-chelating properties of carnosine we 
investigated whether MGO-induced toxicity can be mitigated by carnosine. This was 
studied in a chronic manner by exposing HUVECs for 7 days to MGO and more 
acutely in a type of “wound healing” setting, i.e. by assessing the ability of endothelial 
cells to repair a damage monolayer in the presence or absence of MGO.  
Under MGO chronic exposure conditions, cell detachment was clearly visible already 
after 1 day of MGO treatment. Although at day 1 cell morphology was slightly 
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improved by 20 mM of L-carnosine, on subsequent days the endothelial cell 
monolayer greatly improved only when carnosine was present in the cell culture 
medium. This was substantiated by an increased number of cells attached to the 
culture plate which further proliferated, while in the absence of carnosine this was not 
observed Fig.12 
Fig.12.  Carnosine prevents toxicity under MGO chronic challenge conditions. HUVECs were 
cultured for various time points in the presence of 800µM MGO (panel in the middle) or in the 
presence MGO and 20Mm Carnosine (lower panel). HUVECs cultured in normal medium (upper 
panel) served as control. Phase-contrast microscopy pictures were taken at 1, 3, 5 and at 7 days to 
assess morphological changes, magnification10x. 
 
 
The results found in the chronic exposure experiments were in concordance to the 
results from the endothelial cell scratch assay. While in the control monolayers a 
complete recovery occurred within 24 hrs after initiation of the scratch, in the 
presence of MGO cells started to detach resulting in a complete disruption of the cell 
monolayer. At early time points (1 and 6 hrs) carnosine did not affect impairment of 
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the monolayer. However, at later time points (24 and 48 hrs) cell motility and 
proliferation appeared to recover, although to a lesser extent compared to untreated 
cells (Fig. 13). 
 
Fig. 13. Carnosine improves cell migration and proliferation in MGO treated cells.   
Confluent HUVECs were challenged with 800µM MGO in the absence or presence of 20Mm 
Carnosine (Car). A scratch with a p20 pipette tip was performed in the monolayer and the closure of 
the wound was imaged over 48 hours. Phase-contrast microscopy pictures of the wound area were 
taken at 1, 6, 24 and 48 hours after the scratch. The figure shows pictures of the extend of the 
closure obtained under control conditions (upper row), cells treated with 800 µM MGO (middle row) 
and cells treated with 800µM MGO and 20mM Carnosine (lower row). Red lines represent the border 
of the initial scratch. magnification10x.   
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 Characterization of a green fluorescent protein (roGFP)-based redox 3.6
biosensor 
Changes in the reduction-oxidation (redox) state within cells and organisms are 
important reactions occurring in normal physiological processes like cell proliferation 
and growth but also in conditions where elevated and prolonged oxidative stress play 
a pivotal role, such as in diabetes and diabetes-related vascular complications.  
In this paragraph we characterized a cytosolic green fluorescent protein (roGFP)-
based redox sensor that allows the dynamic analysis of the redox state, with the 
intention to assess if MGO and or carnosine affect the intracellular redox milieu. This 
sensor is equipped with a redox-sensitive green fluorescent protein (GFP) that by the 
introduction of cysteine groups into the protein structure can modify its fluorescent 
properties. The fusion of the human enzyme glutaredoxin (Grx-1) which functions as 
glutathione-dependent oxidoreductase facilitates a specific, fast, dynamic and live 
visualization and measurement of the glutathione redox potential. 
 
To explore the sensitivity of the roGFP redox sensor in living cells, we tested its 
response to exogenous added H2O2 and dithiothreitol (DTT), agents with well-known 
oxidizing and reducing properties, respectively. Addition of 50µM H2O2 in the medium 
of roGFP transduced HUVECs led to a strong and immediate oxidative response, 
evidenced by an increase in the excitation ratio (395/485 nm), and remained in the 
oxidative state until injection of 500µM DTT (Fig.14 A). These results indicate that 
roGFP is sensitive and respond within seconds to changes in the cell redox state. Of 
note, no changes in the redox potential were observed in non- transduced cells (data 
not shown). 
To examine the sensitivity of roGFP to different concentrations of H2O2, dose 
response experiments with concentrations within the µM range were performed. 
Injection of as little as 6 µM H2O2 was sufficient to elicit a rapid increased of the 
excitation ratio. Consequently, injection of higher H2O2 concentrations i.e. 25µM and 
50µM induced a higher increase in the excitation ratio which prolonged over 60 
minutes (Fig.14 B).   
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Fig.14 roGFP fusion protein allows dynamic visualization of rapid intracellular redox changes. 
HUVECs expressing roGFP were excited at 395 and 485 nm, and the ratio of emission at 528 was 
calculated and plotted against time (x axis). (A) Cells were treated with 50µM H202 followed by 
addition of 500µM DTT (dithiothreitol) 30 seconds later. (B) roGFP–expressing HUVECs were treated 
with the indicated concentrations of H202 at 1 minute and the radiometric sensor response was 
measured over time. (C) roGFP–expressing Huvecs were treated with one bolus of 50µM H202 at 2 
minutes. Recovery of the cells from the oxidative state is evidenced by a gradual decline of the 
excitation ratio. After 77 minutes a second bolus of 50µM H202 was injected accompanied with a 
slower recovery from the oxidative state. 
 
 
To examine the recovery of the HUVECs during repetitive oxidative injections, 
roGFP-expressing cells were consecutively challenged with H2O2. When cells were 
challenged for the first time with 50µM of H2O2 the excitation ratio rapidly increased 
followed by a gradual decline to near baseline in approximately 77 minutes. Also the 
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second H2O2 challenge resulted in a rapid increase of the excitation ratio, but the 
decline was much slower. Indeed, 77 minutes after the second injection the excitation 
ratio remained at the level of 1.20 pointing out that 94% of the roGFP-expressing 
cells were still in an oxidative state (Fig.14 C).    
 
Since it has been suggested that endogenous oxidant levels are dependent on cell 
number, we tested whether the redox potential is influenced by cell density. roGFP- 
expressing HUVECs cells were seeded at different densities and the redox potential 
at baseline was determined. An association between cell density and redox state was 
observed. Accordingly, a higher cell density e.g. 40.000 cells/well led to a lower 
excitation radio whereas a low cell density (10.000 cells/well) was associated with a 
higher ratio (Fig.15 A). To assess the response and recovery of different cells 
densities towards oxidative stress, we challenged cells seeded at different densities 
with 50µM H2O2 and the redox state was monitored overt 50 minutes. 
Interestingly, after an acute H2O2 injection, cells with the higher density showed a 
tendency towards a faster recovery reflected by a more rapid decline of the excitation 
ratio over time (Fig.15 B).  
 
 
Fig.15. Cell density influences baseline redox state and recovery from oxidative stress. roGFP- 
expressing HUVECs were seeded at different densities (10.000, 25.000 and 40.000 cells/0.32 cm2) 
and the excitation ratio at baseline was determined (A). After 5 minutes 50µM H202 was injected and 
the redox response was monitored over a 50-minute time frame. Error bars represent mean and SD. 
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Having assessed the characteristics of the roGFP-sensor we next studied the 
behavior of MGO and/or carnosine in this system.  
Since morphological changes and decreased cell viability were previously observed 
with 200, 400 and 800µM MGO, roGFP expressing cells were challenged with similar 
concentrations. The redox response was monitored over a time frame of 30 minutes 
and compared to the redox changes elicited by a single bolus of 50µM H2O2. 
 A rapid increase from 1.0 to 1.7 in the excitation ratio was observed with 50µM H2O2 
injection. In contrast, MGO elicited only a minimal increase in excitation ratio, by far 
less compared 50µM H2O2 (Fig.16 A). Since MGO-induced ROS production is likely 
to be time-dependent, cells were injected with 800µM MGO and the redox response 
was monitored over a longer period of time.  
Directly before the challenge with MGO and at the end of the experiment changes in 
cell morphology were assessed by microscopy (Fig.16 C). While at 800µM MGO a 
clear cell morphological change was observed at the end of the response period, 
MGO elicited only a mild net increase of 0.2 in the excitation ratio which maintained 
during the time frame of 250 minutes without any further increase. Thus, compared to 
the oxidative response elicited by 50µM H2O2, changes in the excitation ratio by high 
concentrations of MGO are extremely low (Fig.16 C). 
 
To test whether carnosine influences the intracellular redox milieu, roGFP-expressing 
HUVECs were first treated with 50 µM of H2O2 and after 10 minutes, when the 
excitation ratio remained at a plateau, either with DTT or 20mM of carnosine were 
added.  Both compounds were able to decrease the excitation ratio to a similar extent 
(Fig. 16 B).  
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Fig.16 Redox response of roGFP- expressing cells to MGO and carnosine. (A) roGFP-expressing 
HUVECs were challenged at time = 5 minutes with different concentrations of MGO or 50µM H2O2.  
The redox response was monitored for a total time frame of 30 minutes. (B) HUVECs expressing 
roGFP were challenged with 50µM H2O2 to elicit an increased excitation ratio. At time = 20 minutes 
either 20 mM of L-carnosine or 500µM DTT was added. Note that the addition of either of these 
compounds elicited an immediate decrease in excitation ratio. (C) roGFP-expressing HUVECs were 
challenged with 800µM of MGO and the redox response was monitored over 250 minutes. 
Simultaneously, morphologic changes induced by 800µM MGO treatment were assessed by phase 
microscopy,magnification(10x) 
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4 DISCUSSION 
 Detection of Carnosinase1 in urine 4.1
 
Numerous studies have reported on CN1 in serum and cerebrospinal fluid (CSF). 
This is not surprising based on its tissue expression profile and the fact that CN1 is 
targeted to the secretory pathway76. The results described herein indicate that 
besides serum and CSF, CN1 is also present in human urine.  
The ELISA system employed herein has a high specificity as CN1 was undetectable 
in urine and serum of wild type mice, and measurable in serum (8.7- 30.4 µg/ml) and 
in urine (0 – 930.5 ng/ml) of transgenic animals overexpressing human CN1. 
However, it should be noted, that our ELISA system cannot differentiate between the 
different CN1 conformations i.e. monomers or homodimers. 
Importantly, we were unable to detect any enzymatic activity of natural occurring CN1 
in human or mouse urine. Yet, and as reported for other enzymes secreted in urine, 
lack of enzyme activity might be caused by several unfavorable factors intrinsic to 
urine i.e. high urea concentrations, longstanding retention in the bladder and low pH 
93,94. Accordingly, the reported pH activity curve of CN1 shows a maximum between 
pH 7.5 - 8.5 76.Of note, the enzymatic activity of CN1 recombinant protein spiked in 
urine was measurable, although in a lesser extent compared to the recombinant CN1 
spiked in assay buffer (5.7 µM/ml/h vs 6.4 µM/ml/h). This strengthens the argument 
that urine may inhibit CN1 enzymatic activity. Based on these observations one 
would expect that longer incubations of the recombinant CN1 protein in urine might 
completely abolish enzymatic activity, however this was not assessed in the present 
study. 
 
 Characterization of 24-hr urinary CN1 in living kidney donors and patients 4.2
with T2DM (DIALECT cohort) 
To assess the relevance of urinary CN1 for renal function impairment in T2DM 
patients, CN1 was measured in 24-hr urine samples from patients with T2DM and 
living kidney donors (healthy subjects). Urinary CN1 was detected in 74% of the 
healthy subjects. In the group of diabetic patients, the proportion of urine samples in 
which CN1 was detected increased in parallel with the degree of albuminuria from 
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61% in the normoalbuminuric group, to 81% in the microalbuminuria group. In T2DM 
patients with macroalbuminuria, nearly all the urine samples (97%) were positive for 
CN1. In line with this, our results also show that high urinary CN1 excretion rates in 
T2DM patients correlates with increased albuminuria and low eGFR, which are the 
main prognostic predictors of diabetic nephropathy 95. Likewise, glycosuria appeared 
to be an independent factor influencing urinary CN1 concentrations. 
 
An intrinsic carnosine metabolism in the human kidney has been reported based on 
the presence of carnosine synthesizing and degrading enzymes, i.e. carnosine 
synthase (CARNS) and CN1 respectively90. Immune-histological studies in human 
kidneys, suggest that these enzymes are expressed in different compartments of the 
nephron. While carnosine synthesis in the proximal tubule might  be important for 
protecting renal tissue from oxygen radicals, degradation of carnosine by CN1 in the 
distal tubule might play a role in maintaining a low pH, required for the exchange of 
H+ with K+ and Na+ ions in this compartment, as previously suggested by Peters et.al 
90. 
Glomerular filtration is restricted by the size and charge barrier of the glomerular 
basement membrane and the underlying slit diaphragm. It is believed that small 
negatively charged proteins such as albumin are not completely retained by the 
glomerular filtration barrier. Most of the filtrated albumin, does however not reach the 
lower urinary system as it is reabsorbed in the proximal tubule. In view of the 
molecular weight (~65kDa) and the isoelectric point of CN1 monomers, it is 
conceivable that monomeric CN1 may pass the filtration barrier with similar sieving 
characteristics as for albumin (~67kDa). In its homodimer conformation(~130kDa), 
which is believed to be the major conformation of CN1 in serum 96, CN1 is thus too 
large to cross the glomerular filtration barrier.  
Small molecules like organic anions and cations (H+, creatinine, drug metabolites, 
etc.) are cleared from the blood via tubular secretion. This process requires specific 
transporters and mostly occurs in the proximal tubule and to a lesser extent in other 
segments of the nephron. Because tubular secretion is highly selective and  CN1 
transporters are not known to be present in the kidney, the presence of CN1 in urine 
cannot be explained by tubular secretion. Therefore, the appearance of CN1 in urine 
of healthy individuals might be due to 1) filtration of small amounts of CN1 monomers 
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from the circulation or 2) local renal production and secretion of CN1 into the tubular 
lumen.  
 
In the T2DM group, CN1 was detected in nearly all patients. Among these patients, 
urinary CN1 excretion rates were significantly higher in patients with 
macroalbuminuria. Considering that the glomerular filtration barrier is severely 
impaired in such patients it is concievable that, like albumin, CN1 will appear in the 
urine, which also explains the positive association between albuminuria and urinary 
CN1. Importantly, urinary CN1 excretion rates did not differ between healthy subjects 
and T2DM patients with microalbuminuria, presumably because the amount of 
filtered CN1 did not exceed the tubular reabsorption capacity in these patients. Thus, 
we speculate that similar as in healthy individuals, CN1 is predominately derived from 
local renal synthesis, or filtration of CN1 monomers in patients with microalbuminuria, 
rather than from glomerular filtration.  
 
Typically, in the course of DN, an increase in albuminuria precedes the decline in 
glomerular filtration rate. The results herein show that T2DM patients with kidney 
disease, as reflected by poor eGFR, display high urinary CN1 excretion rates. 
Multivariate linear regression analysis suggests that both albuminuria and eGFR can 
be considered as independent factors associated with urinary CN1. Hence, our 
findings suggest that urinary CN1 excretion increases along with renal function 
deterioration, yet they also warrant further large prospective studies to confirm these 
cross-sectional findings. Likewise, glycosuria also appeared as an independent factor 
positively associated with urinary CN1. If CN1 is locally synthesized in the kidney, it 
is possible that high glucose levels in the tubular lumen enhance CN1 secretion, 
similar as described by Riedl et. al 97. 
 
 Association of serum CN1 and CNDP1 genotype with urinary CN1 in patients 4.3
with T2DM and non-diabetic chronic kidney disease (Mannheim Cohort). 
 
Proteinuria, routinely assessed in patients with chronic kidney disease (CKD), is a 
well-established biomarker for the progression of renal function deterioration98. 
Assessment of proteinuria based on 24-hr urine collection has been considered as 
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the gold standard. Yet, because of its inconvenience and collection inaccuracies 99,100 
clinical practice guidelines  suggest first void or spot urine albumin-to-creatinine ratio 
(ACR) as a surrogate of  the  albumin excretion rate101. 
To test if our findings in 24-hr urine would be similar as in spot urine (Results, section 
3.2) we performed a feasibility study in a smaller group of CKD patients to assess the 
relation between CN1 in spot urine, ACR and renal function. Additionally, the 
influence of serum CN1 concentrations and CNDP1 genotype on urinary CN1 
expression was tested.  
In agreement with the observations described in section 3.2 we found that urinary 
CN1 is more frequently detected and displays higher concentrations in patients with 
macroalbuminuria as compared to those with microalbuminuria. 
In a similar fashion, a strong positive correlation between urinary CN1 and ACR was 
found (r=0.66, p <0.0001). Furthermore, patients with strongly to moderately impaired 
renal function (eGFR <60ml/min) displayed higher urinary CN1 concentrations 
compared to patients with preserved renal function (147.5 vs 17 ng/ml, p=0.015). 
In multivariate regression analysis, ACR and serum CN1 concentrations appeared as 
independent predictors of urinary CN1, explaining together 44 % of variation of 
urinary CN1 concentrations (R2 = 0.44, p<0.0001). These data are concordant to our 
previous results using 24-hr urine samples and thus suggest that spot urine can be 
used for the assessment of CN1 in biorepositories in which spot - rather than 24-hr 
urine samples were collected.  
 
Based on the findings that urinary CN1 concentrations are increased in patients with 
macroalbuminuria, one would expect that as a result of an impaired glomerular 
barrier, serum CN1 concentrations would be decreased in this group. Contrary to our 
expectations, no differences in serum CN1 concentration were found between 
patients with micro and microalbuminuria.  
Nonetheless, lower serum CN1 concentrations were observed in all patients when 
compared to the healthy group. In this regard, one of the possible factors influencing 
serum CN1 concentrations is the high prevalence of protein energy wasting, defined 
as a “state of decreased body stores of protein and energy fuels”, among patients 
with CKD102. In support of this, low serum CN1 concentrations have also been 
reported in pathologies characterized by a high catabolic state, e.g. neoplasia and 
liver cirrhosis 103–105, making protein energy wasting, a likely factor influencing serum 
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CN1 concentrations in patients with residual renal function. Alternatively, dialysis per 
se and metabolic acidosis, a common comorbidity of CKD, can promote enhanced 
protein breakdown and amino acid oxidation 106,107. 
Yet, the strong correlation between urinary CN1 concentrations and albuminuria 
suggests that increasing CN1 concentrations likely reflects impairment of the 
glomerular filtration barrier. This may also partly explain the positive correlation 
between serum CN1 and urinary CN1 concentrations in patients but not in healthy 
controls (data not shown), as in patients with an impaired glomerular filtration barrier 
such a correlation would be expected.  
In the multivariate regression model serum CN1 was identified as independent 
predictor of urinary CN1 concentrations. Likewise, positive correlations between 
albumin synthesis and albumin urinary excretion have been reported in patients with 
macroalbuminuria108.  
 
Inasmuch as renal CN1 mRNA and protein expression have been reported 77,79,90 to 
the best of our knowledge there are no studies that provide direct evidence for renal 
CN1 secretion into the renal tubular lumen. Yet, the lack of correlation between 
serum and urinary CN1 concentrations in healthy individuals argues against a free 
communication between the circulatory and urinary compartment and tempted us to 
presume that urinary CN1 in healthy conditions is a consequence of renal production 
and secretion. Nonetheless, it cannot be excluded that  if serum CN1 partly exist in a 
monomeric conformation it might pass the filtration barrier109. 
In contrast to serum CN1 concentrations, it appeared that urinary CN1 
concentrations were not influenced by the CNDP1 (CTG)n polymorphism. Since it has 
been shown that variations in the leucine repeat in the signal peptide of CN1 affects 
CN1 secretion  this would  have also been expected for renal CN1 secretion88. If, 
however monomeric serum CN1 is filtered, urinary CN1 concentrations will correlate 
more with the fraction of monomeric CN1 rather than the CNDP1 genotype. Of note, 
our in-house ELISA used for CN1 detection cannot distinguish between CN1 
monomers and dimers and the small amount of CN1 as well as the presence of urea 
in the urine samples also hamper drawing firm conclusions in Westernblotting 
experiments. 
Although patients with low eGFR appeared to have higher urinary CN1 
concentrations compared to patients with preserved renal function (<60 ml/min) and 
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the univariate analysis revealed a significant negative correlation between eGFR  
and urinary CN1, the subsequent  multivariate regression model  excluded  eGFR  as 
an  independent explanatory factor for urinary CN1. This could be explained by 1) the 
current study population in overall has considerable renal function impairment 
compared to  the subjects studied in section 3.2 and thus it is conceivable that in late 
stages of disease, eGFR to a lesser extend influences urinary CN1 concentrations; 
2) A possible collinearity between the variables eGFR and ACR may add similar 
information and thus only the variable with the strongest relationship is included in 
the final  regression model110.  
Multivariate linear regression analysis revealed that albuminuria (ACR) and serum 
CN1 can be considered as independent predictors of urinary CN1 in non-diabetic and 
diabetic patients with CKD. If we speculate that in this group of patients, the majority 
of detected CN1 in urine originates from the circulation, these findings might imply 
that concentrations of CN1 in urine is a function of two independent processes: on 
one hand the change in glomerular permselectivity reflected by a strong positive 
correlation with albuminuria and on the other hand the ability of the liver to maintain 
CN1 production. 
Even though the findings herein are in concordance with the observations drawn 
from the 24-hr urine, there are some limitations. Firstly, the number of healthy 
controls is relatively small and healthy controls were not matched for gender and age 
with the patient’s cohort. Hence, conclusions based on any direct comparisons 
between patients and controls cannot be firmly drawn and should be taken with 
caution. Secondly, it would be useful to directly compare 24-hr urine and spot urine of 
the same individual. We are aware that this would have been the most ideal situation, 
however, at the time of study 24-hr urine samples were not available for most of the 
patients. The intention of this study was to assess the feasibility of meaningful 
measuring urinary CN1 concentrations in spot urine.  
 
 Toxicity profile of Methylglyoxal in human vascular endothelium 4.4
 
Compelling evidence suggest that glycation may play a role in the pathophysiology of 
microvascular complications. MGO, the prototypical RCS, has been found to 
accumulate in tissues under diabetic conditions. We studied the susceptibility of 
cultured human vascular endothelial cells towards MGO.  
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MGO dose-dependently decreased the viability of HUVECs when challenged for 24 
hrs. This was most pronounced for concentrations of 400 and 800µM of MGO. Our 
findings are in concordance with previous reports where cytotoxicity was seen in a  
similar concentration ranges111. MGO also increased the number of TUNEL positive 
cells, yet the percentage hereof was low (approximately 10%) and thus DNA damage 
alone cannot explain MGO’s toxicity.  
It should be emphasized that the concentrations used herein and in other studies 
appeared to be higher than levels reported in vivo in T2DM patients, albeit that the 
circulating MGO concentrations reported in humans largely differ between different 
studies. 
Our results also demonstrated that higher cell densities markedly reduced the 
sensitivity of endothelial cells to MGO. The mechanism by which higher cell densities 
decrease susceptibility was not address in this study, but presumably this effect 
underlies a simple decrease in the number of MGO molecules available per cell with 
increasing cell density.. In line with this, different susceptibilities of low and high cell 
densities to other compounds i.e. cadmium and zinc oxide effects have also been 
described112,113. 
Although in this study we did not address the mechanism by which MGO exert 
cytoxicity, it has been reported  that MGO can induce apoptosis by caspase 
activation, suppression of the anti-apoptotic proteins  Bcl-2 and XIAP(X-linked 
inhibitor of pro-apoptosis protein) and by upregulation of proapoptotic signals such as 
Bax111,114. Considering this, one would expect that at high MGO concentrations, the  
majority of cells, if not all, would be TUNEL positive. Hence our data suggest that 
other cell death mechanisms, such as necrosis may occur upon a challenge with high 
MGO concentrations. In line with this assumption, a recent study in epithelial cells 
demonstrated that MGO treatment indeed triggers both necrosis and apoptosis115. 
 
 Carnosine treatment ameliorates MGO-induced toxicity 4.5
 
Carnosine has been repeatedly described as a RCS scavenger, by forming stable 
adducts through covalent bonds with RCS116. In vivo studies have shown that 
carnosine supplementation in Zucker rats and BTBRob/ob mice results in an increased 
amount of carnosine-HNE-MA, carnosine-DHN and 3-HPMA adducts in urine along  
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with a decrease of urinary markers of protein carbonylation65,117. The authors suggest 
that this might be a means to detoxify and remove RCS from the body. Our own data 
are to some extent in line with this assumption, as it demonstrates the beneficial 
effect of carnosine on MGO-mediated toxicity, suggesting a potential role in 
detoxification by carnosine. Nonetheless, it should be underscored that the 
quenching activity of carnosine is strong towards α and β unsaturated carbonyls, but 
rather poor for dicarbonyls such as MGO116. A more recent study revealed that 
carnosine catalyzes the formation of  transient MGO oligomers  rather than forming a 
stable covalent bond118. Hence, carnosine’s protective effects reported herein are 
unlikely due to its scavenging ability, but rather to other mechanisms involved in the 
carnosine-MGO interaction. Since MGO also induces oxidative stress in endothelial 
cells, we postulated that carnosine’s protective effects might be explained by its 
antioxidative properties. Alternatively, carnosine might also act extracellularly 
preventing cellular uptake of MGO, as proposed by others118. A recent study in 
human endothelial cells, demonstrated that carnosine can reverse MGO-induced 
effects on expression of cell cycle-associated genes.51 Of note, the protective effect 
of carnosine on cell viability was not assessed by MTT assay, but was based on the 
morphological changes observed upon co-treatment with carnosine.  
 
 
 Characterization of a green fluorescent protein (roGFP)-based redox     4.6
biosensor 
 
Fluorescent based redox probes have important advantages such as high specificity 
and easy subcellular targeting. The sensor described herein is based on the ability of 
RoGFP to become oxidized or reduced in response of changes in the cytosolic redox 
couple  GSH/GSSG  acting as a Grx-1 target protein57.The roGFP sensor described 
in the experimental part of this thesis was constructed by substitution of specific 
surface-exposed residues with cysteines that have not been reported elsewhere. It 
has two fluorescence excitation maxima at 395 and 485 and an emission peak at 
528nm. In principal, any compound that interacts with the equilibrium between 
GSH/GSSG can be screened with this biosensor.   
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Our results confirmed the observations of Gutscher et. al, suggesting that the fusion 
of Grx-1 facilitates a rapid visualization of glutathione redox changes57. Furthermore, 
the sensor responds to concentrations as low as 6µM of exogenously added 
oxidizing agents such as H202.  The effect of cell density on the redox status  
previously reported  was also observed in our hands57. 
 
It has been reported that MGO promotes oxidative stress by inducing the production 
of ROS which in turn might change the redox potential119. Based on this, we 
investigated whether MGO-induced ROS can be detected by roGFP-expressing 
HUVECs. Against our expectations, we did not observe changes in the redox status  
upon short (30 mins) and  long treatment  with MGO (250 mins) (Fig.16. A,C). As 
such, attempts to detect MGO-induced ROS were not successful, even though it is 
reported that MGO detoxification through the glyoxalase (GLO) pathway is 
glutathione (GSH)-dependent. Masterjohn et al. described that acute glutathione 
depletion induces MGO accumulation by impairing its detoxification120.  
Our findings were unexpected since MGO clearly inflicts morphological changes after 
short times of incubation (Fig. 13). Additionally, it is reported that MGO-induced H202 
generation is detected at 15 min (47.5%) and increases to 96.7% at 1 hour in 
comparison to untreated cells115. In a previous version of roGFP, Dooley et.al were 
also unable to demonstrate any response to stimuli reported to generate intracellular 
H202
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 . 
MGO is mainly detoxified by the glyoxalase system and its cofactor, GSH,  it is not 
depleted but recycled back into the system121. Hence, there is no net change in GSH 
concentrations, which might explain why our roGFP sensor does not show 
fluctuations in the redox status upon an MGO challenge.  Importantly, and similar to 
DTT, our results also showed that carnosine decreases the excitation ratio after H202 
injection, thus confirming its anti-oxidative properties. 
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5 CONCLUSION 
Our studies demonstrate for the first time that CN1 can be detected in spot and 24-hr 
urine of healthy individuals, patients with T2DM and non-diabetic CKD. These 
findings are compatible with previous immune-histological and mRNA data that 
showed that CN1 is expressed in  human renal tissue90. The physiological role of 
urinary CN1 is, however, still elusive and warrants further studies to assess its 
relevance for renal carnosine stores. Furthermore, our results suggest that the in-
house ELISA system can be employed to measure CN1 in different matrixes i.e. 
serum and urine, from both human and mouse.  
 
Urinary CN1 concentrations appeared to be increased in patients with 
macroalbuminuria regardless of the baseline disease, and to be associated with renal 
function. Noteworthy, the correlation coefficient between urinary CN1 and 
albuminuria (ACR) in spot urine (section 3.3) was higher and the model goodness of 
fit was even better than the one reported in the 24-hr urine study (section 3.2) 
 (r = 0.59 vs 0.66) and (R2= 0.37, p<0.0001 vs 0.44, p<0.0001). The strong 
correlations found and the confirmatory nature of the data indeed suggest that 
urinary CN1 can be reliably measured in spot urine and warrants further studies in 
large cohorts to assess the potential relevance hereof for renal function deterioration.  
The confirmation and reproducibility of the findings from the 24-hr urine study in the 
present data suggest that the assessment of CN1 in spot samples can be considered 
as reliable as in 24-hr samples.  
 
Our in vitro studies suggest that MGO affects cell viability in a dose dependent 
manner. Based on the low cell number positive for TUNEL, we assume that MGO-
induced cell death is not completely mediated through apoptosis. Carnosine 
appeared to counteract MGO-induced toxicity in vitro. Since there is no reported 
evidence for scavenging of MGO by carnosine, the beneficial effects of carnosine 
might be due to its antioxidant properties rather than through a scavenging 
mechanism
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